

Safety and immunogenicity of an rAd26 and rAd5 vector
COVID-19 vaccine in two formulations: two open, non-r
Russia

Lancet, The

396, 887-897

DOI: [10.1016/s0140-6736\(20\)31866-3](https://doi.org/10.1016/s0140-6736(20)31866-3)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Understanding the dynamics of COVID-19; implications for therapeutic intervention, vaccine development and movement control. <i>British Journal of Biomedical Science</i> , 2020, 77, 168-184.	1.2	12
2	A systematic review of SARS-CoV-2 vaccine candidates. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 237.	7.1	427
3	SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. <i>Lancet, The</i> , 2020, 396, 1595-1606.	6.3	511
4	SARS-CoV-2 vaccines in development. <i>Nature</i> , 2020, 586, 516-527.	13.7	1,659
6	Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. <i>Lancet, The</i> , 2020, 396, 1979-1993.	6.3	1,196
7	Detection, Mapping, and Proteotyping of SARS-CoV-2 Coronavirus with High Resolution Mass Spectrometry. <i>ACS Infectious Diseases</i> , 2020, 6, 3269-3276.	1.8	34
8	The immunology of SARS-CoV-2 infections and vaccines. <i>Seminars in Immunology</i> , 2020, 50, 101422.	2.7	85
9	Leadership in a time of crisis: Lessons learned from a pandemic. <i>Bailliere's Best Practice and Research in Clinical Anaesthesiology</i> , 2021, 35, 405-414.	1.7	23
10	Application of Viral Vectors for Vaccine Development with a Special Emphasis on COVID-19. <i>Viruses</i> , 2020, 12, 1324.	1.5	35
12	SARS coronavirus 2: from genome to infectome. <i>Respiratory Research</i> , 2020, 21, 318.	1.4	62
13	Update in COVID-19 in the intensive care unit from the 2020 HELLENIC Athens International symposium. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2020, 39, 723-730.	0.6	22
14	Vaccines against COVID-19. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2020, 39, 703-705.	0.6	31
15	An update on the global vaccine development for coronavirus. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2020, 14, 2053-2055.	1.8	20
16	COVID-19 vaccines: early success and remaining challenges. <i>Lancet, The</i> , 2020, 396, 868-869.	6.3	29
17	Safety and efficacy of the Russian COVID-19 vaccine: more information needed – Authors' reply. <i>Lancet, The</i> , 2020, 396, e54-e55.	6.3	25
18	Safety and efficacy of the Russian COVID-19 vaccine: more information needed. <i>Lancet, The</i> , 2020, 396, e53.	6.3	27
19	Don't shortchange public trust in science. <i>Nature Cancer</i> , 2020, 1, 855-856.	5.7	0
20	Cardiovascular Complications Associated with COVID-19 and Potential Therapeutic Strategies. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6790.	1.8	52

#	ARTICLE	IF	CITATIONS
21	Vaccines for COVID-19. <i>Clinical and Experimental Immunology</i> , 2020, 202, 162-192.	1.1	185
23	Coronavirus vaccine development: from SARS and MERS to COVID-19. <i>Journal of Biomedical Science</i> , 2020, 27, 104.	2.6	287
24	Will SARS-CoV-2 Infection Elicit Long-Lasting Protective or Sterilising Immunity? Implications for Vaccine Strategies (2020). <i>Frontiers in Immunology</i> , 2020, 11, 571481.	2.2	48
25	COVID-19: Coronavirus Vaccine Development Updates. <i>Frontiers in Immunology</i> , 2020, 11, 602256.	2.2	143
26	Navigating the Quagmire: Comparison and Interpretation of COVID-19 Vaccine Phase 1/2 Clinical Trials. <i>Vaccines</i> , 2020, 8, 746.	2.1	6
27	Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence. <i>Science Immunology</i> , 2020, 5, .	5.6	244
28	Current Prevention of COVID-19: Natural Products and Herbal Medicine. <i>Frontiers in Pharmacology</i> , 2020, 11, 588508.	1.6	99
29	In Pursuit of a SARS-CoV-2 Vaccine. <i>Journal of Foot and Ankle Surgery</i> , 2020, 59, 1133-1134.	0.5	1
30	The roles of nausea and vomiting in COVID-19: did we miss something?. <i>Journal of Microbiology, Immunology and Infection</i> , 2021, 54, 541-546.	1.5	20
31	COVID-19 lockdown: animal life, ecosystem and atmospheric environment. <i>Environment, Development and Sustainability</i> , 2021, 23, 8161-8178.	2.7	50
32	A promising inactivated whole-virion SARS-CoV-2 vaccine. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 2-3.	4.6	15
33	Learning from the past: development of safe and effective COVID-19 vaccines. <i>Nature Reviews Microbiology</i> , 2021, 19, 211-219.	13.6	126
34	T cell immunity to SARS-CoV-2 following natural infection and vaccination. <i>Biochemical and Biophysical Research Communications</i> , 2021, 538, 211-217.	1.0	88
35	Racing to immunity: Journey to a COVID-19 vaccine and lessons for the future. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3408-3424.	1.1	16
36	Development of SARS-CoV-2 vaccines: challenges, risks, and the way forward. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 1635-1649.	1.4	14
37	SARS-CoV-2: Targeted managements and vaccine development. <i>Cytokine and Growth Factor Reviews</i> , 2021, 58, 16-29.	3.2	44
38	Prevention and treatment of COVID-19: Focus on interferons, chloroquine/hydroxychloroquine, azithromycin, and vaccine. <i>Biomedicine and Pharmacotherapy</i> , 2021, 133, 111008.	2.5	40
39	COVID-19: A review of therapeutic strategies and vaccine candidates. <i>Clinical Immunology</i> , 2021, 222, 108634.	1.4	180

#	ARTICLE	IF	CITATIONS
40	Therapeutic and Vaccine Options for COVID-19: Status after Six Months of the Disease Outbreak. <i>SLAS Discovery</i> , 2021, 26, 311-329.	1.4	4
41	Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. <i>Nature Medicine</i> , 2021, 27, 279-288.	15.2	265
42	Viral targets for vaccines against COVID-19. <i>Nature Reviews Immunology</i> , 2021, 21, 73-82.	10.6	832
43	The management of hematologic malignancies during the COVID-19 pandemic. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 565-582.	0.9	9
44	SARS-CoV-2 candidate vaccines – composition, mechanisms of action and stages of clinical development. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1922-1924.	2.7	23
46	COVID-19. <i>Critical Care Nursing Quarterly</i> , 2021, 44, 128-137.	0.4	17
47	An update on coronavirus disease-19 vaccines. <i>Journal of Medical Evidence</i> , 2021, 2, 24.	0.2	2
48	Isolating SARS-CoV-2 Strains From Countries in the Same Meridian: Genome Evolutionary Analysis. <i>JMIR Bioinformatics and Biotechnology</i> , 2021, 2, e25995.	0.4	6
49	A novel DNA and protein combination COVID-19 vaccine formulation provides full protection against SARS-CoV-2 in rhesus macaques. <i>Emerging Microbes and Infections</i> , 2021, 10, 342-355.	3.0	37
50	Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates. <i>Emerging Microbes and Infections</i> , 2021, 10, 629-637.	3.0	118
51	Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine. <i>Emerging Microbes and Infections</i> , 2021, 10, 1598-1608.	3.0	76
52	Older adults: panoramic view on the COVID-19 vaccination. <i>AIMS Public Health</i> , 2021, 8, 388-415.	1.1	14
55	Pandemic Viruses at Hajj: Influenza and COVID-19. , 2021, , 1-19.		0
56	Meteorological parameters and COVID-19 spread-Russia a case study. , 2021, , 179-190.		2
57	Clinical characteristics of headache after vaccination against COVID-19 (coronavirus SARS-CoV-2) with the BNT162b2 mRNA vaccine: a multicentre observational cohort study. <i>Brain Communications</i> , 2021, 3, fcab169.	1.5	48
58	COVID-19: Characteristics and Therapeutics. <i>Cells</i> , 2021, 10, 206.	1.8	177
59	Gamma irradiation-mediated inactivation of enveloped viruses with conservation of genome integrity: Potential application for SARS-CoV-2 inactivated vaccine development. <i>Open Life Sciences</i> , 2021, 16, 558-570.	0.6	8
60	The effects of the Russian vaccine (Sputnik V) on the volunteers. <i>Apollo Medicine</i> , 2021, .	0.0	0

#	ARTICLE	IF	CITATIONS
61	Pandemic Viruses at Hajj: Influenza and COVID-19. , 2021, , 1249-1266.		0
62	An update to "novel therapeutic approaches for treatment of COVID-19". Journal of Molecular Medicine, 2021, 99, 303-310.	1.7	22
63	A COVID-19 Vaccine: Big Strides Come with Big Challenges. Vaccines, 2021, 9, 39.	2.1	78
64	COVID-19 vaccination and allergen immunotherapy (AIT) - A position paper of the German Society for Applied Allergology (AeDA) and the German Society for Allergology and Clinical Immunology (DGAKI). Allergologie Select, 2021, 5, 251-259.	1.6	9
65	An Update on the Pathogenesis of COVID-19 and the Reportedly Rare Thrombotic Events Following Vaccination. Clinical and Applied Thrombosis/Hemostasis, 2021, 27, 107602962110214.	0.7	29
66	Coronavirus disease 2019 vaccines and relevant adverse reactions. Allergy Asthma & Respiratory Disease, 2021, 9, 124.	0.3	3
67	Pathogenesis of Multiple Organ Injury in COVID-19 and Potential Therapeutic Strategies. Frontiers in Physiology, 2021, 12, 593223.	1.3	113
70	Ten principles for generating accessible and useable COVID-19 environmental science and a fit-for-purpose evidence base. Ecological Solutions and Evidence, 2021, 2, e12041.	0.8	8
71	The Worldwide Effort to Develop Vaccines for COVID-19. Advances in Experimental Medicine and Biology, 2021, 1327, 215-223.	0.8	3
72	Long-Term Analysis of Antibodies Elicited by Sputnik V in Tucuman, Argentina. SSRN Electronic Journal, 0, , .	0.4	1
73	Perspective on therapeutic and diagnostic potential of camel nanobodies for coronavirus disease-19 (COVID-19). 3 Biotech, 2021, 11, 89.	1.1	29
74	Advanced Nanobiomedical Approaches to Combat Coronavirus Disease of 2019. Advanced NanoBiomed Research, 2021, 1, 2000063.	1.7	5
75	The 2020 race towards SARS-CoV-2 specific vaccines. Theranostics, 2021, 11, 1690-1702.	4.6	71
76	Anti-science kills: From Soviet embrace of pseudoscience to accelerated attacks on US biomedicine. PLoS Biology, 2021, 19, e3001068.	2.6	42
78	Severe Acute Respiratory Syndrome Coronavirus 2: Manifestations of Disease and Approaches to Treatment and Prevention in Humans. Comparative Medicine, 2021, 71, 342-358.	0.4	3
79	A peptide-based subunit candidate vaccine against SARS-CoV-2 delivered by biodegradable mesoporous silica nanoparticles induced high humoral and cellular immunity in mice. Biomaterials Science, 2021, 9, 7287-7296.	2.6	10
80	SARS-CoV-2 Spike Protein Elicits Cell Signaling in Human Host Cells: Implications for Possible Consequences of COVID-19 Vaccines. Vaccines, 2021, 9, 36.	2.1	41
81	SARS-CoV-2: vaccines in the pandemic era. Military Medical Research, 2021, 8, 1.	1.9	104

#	ARTICLE	IF	CITATIONS
82	Flattening the Curve of COVID-19 Vaccine Rejection—An International Overview. <i>Vaccines</i> , 2021, 9, 44.	2.1	107
83	The hamletic dilemma of patients waiting for kidney transplantation during the COVID-19 pandemic: To accept or not to accept (an organ offer)? <i>Transplant Infectious Disease</i> , 2021, 23, e13560.	0.7	9
85	Vaccines for COVID-19 - state of the art. <i>Revista Brasileira De Saude Materno Infantil</i> , 2021, 21, 13-19.	0.2	22
86	COVID-19 vaccines: implementation, limitations and opportunities. <i>Global Health & Medicine</i> , 2021, 3, 1-5.	0.6	28
87	Point of view on the vaccination against COVID-19 in patients with autoimmune inflammatory rheumatic diseases. <i>RMD Open</i> , 2021, 7, e001594.	1.8	59
88	Sputnik V COVID-19 vaccine candidate appears safe and effective. <i>Lancet, The</i> , 2021, 397, 642-643.	6.3	252
89	Integrated vaccination and physical distancing interventions to prevent future COVID-19 waves in Chinese cities. <i>Nature Human Behaviour</i> , 2021, 5, 695-705.	6.2	111
90	Expert Opinions on the Most Promising Treatments and Vaccine Candidates for COVID-19: Global Cross-sectional Survey of Virus Researchers in the Early Months of the Pandemic. <i>JMIR Public Health and Surveillance</i> , 2021, 7, e22483.	1.2	2
92	Adoptive Immunotherapy beyond CAR T-Cells. <i>Cancers</i> , 2021, 13, 743.	1.7	57
93	Experimental Models of SARS-CoV-2 Infection: Possible Platforms to Study COVID-19 Pathogenesis and Potential Treatments. <i>Annual Review of Pharmacology and Toxicology</i> , 2022, 62, 25-53.	4.2	20
94	SARS-CoV-2 Vaccination for Children—An Open Issue. <i>Pediatric Reports</i> , 2021, 13, 95-97.	0.5	3
96	Winter Is Coming! Clinical, Immunologic, and Practical Considerations for Vaccinating Patients With Inflammatory Bowel Disease During the Coronavirus Disease-2019 Pandemic. <i>Gastroenterology</i> , 2021, 160, 639-644.	0.6	12
97	Codon Usage and Adenovirus Fitness: Implications for Vaccine Development. <i>Frontiers in Microbiology</i> , 2021, 12, 633946.	1.5	10
98	Hyperglycemia at admission is a strong predictor of mortality and severe/critical complications in COVID-19 patients: a meta-analysis. <i>Bioscience Reports</i> , 2021, 41, .	1.1	32
99	COVID-19 vaccines for patients with cancer: benefits likely outweigh risks. <i>Journal of Hematology and Oncology</i> , 2021, 14, 38.	6.9	87
102	A Comprehensive Review of Viral Characteristics, Transmission, Pathophysiology, Immune Response, and Management of SARS-CoV-2 and COVID-19 as a Basis for Controlling the Pandemic. <i>Frontiers in Immunology</i> , 2021, 12, 631139.	2.2	117
103	Capsid and Genome Modification Strategies to Reduce the Immunogenicity of Adenoviral Vectors. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2417.	1.8	17
104	Viral Vectors for COVID-19 Vaccine Development. <i>Viruses</i> , 2021, 13, 317.	1.5	65

#	ARTICLE	IF	CITATIONS
105	COVID-19 Vaccines (Revisited) and Oral-Mucosal Vector System as a Potential Vaccine Platform. <i>Vaccines</i> , 2021, 9, 171.	2.1	43
106	Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. <i>Lancet, The</i> , 2021, 397, 671-681.	6.3	1,339
107	Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 48.	7.1	79
108	Development and deployment of COVID-19 vaccines for those most vulnerable. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	60
109	SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. <i>Npj Vaccines</i> , 2021, 6, 28.	2.9	507
110	SARS-CoV-2 virus: Vaccines in development. <i>Fundamental Research</i> , 2021, 1, 131-138.	1.6	12
111	Pharmacological strategies to prevent SARS-CoV-2 infection and treat the early phases of COVID-19. <i>International Journal of Infectious Diseases</i> , 2021, 104, 441-451.	1.5	14
112	Potential COVID-19 Therapeutic Agents and Vaccines: An Evidence-Based Review. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 429-460.	1.0	22
113	Does COVID-19 Vaccination Warrant the Classical Principle "evidence before treatment"? <i>Medicina (Lithuania)</i> , 2021, 57, 253.	0.8	10
114	Adverse Events Reported From COVID-19 Vaccine Trials: A Systematic Review. <i>Indian Journal of Clinical Biochemistry</i> , 2021, 36, 427-439.	0.9	175
115	The conundrum of current anti-SARS-CoV-2 vaccines. <i>Cytokine and Growth Factor Reviews</i> , 2021, 60, 46-51.	3.2	6
118	The potential neurological effect of the COVID-19 vaccines: A review. <i>Acta Neurologica Scandinavica</i> , 2021, 144, 3-12.	1.0	85
119	An Overview of Nanocarrier-Based Adjuvants for Vaccine Delivery. <i>Pharmaceutics</i> , 2021, 13, 455.	2.0	55
120	Development of COVID-19 vaccines utilizing gene therapy technology. <i>International Immunology</i> , 2021, 33, 521-527.	1.8	19
122	COVID-19 vaccines: rapid development, implications, challenges and future prospects. <i>Human Cell</i> , 2021, 34, 711-733.	1.2	227
123	Immunity to SARS-CoV-2: Lessons Learned. <i>Frontiers in Immunology</i> , 2021, 12, 654165.	2.2	33
125	SARS-CoV-2 Neutralizing Antibodies: A Network Meta-Analysis across Vaccines. <i>Vaccines</i> , 2021, 9, 227.	2.1	47
126	Target Product Profile Analysis of COVID-19 Vaccines in Phase III Clinical Trials and Beyond: An Early 2021 Perspective. <i>Viruses</i> , 2021, 13, 418.	1.5	51

#	ARTICLE	IF	CITATIONS
127	Allergic Reactions to Current Available COVID-19 Vaccinations: Pathophysiology, Causality, and Therapeutic Considerations. <i>Vaccines</i> , 2021, 9, 221.	2.1	132
128	COVID-19 in early 2021: current status and looking forward. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 114.	7.1	191
129	COVID-19 Reinfection in the Face of a Detectable Antibody Titer. <i>Cureus</i> , 2021, 13, e14033.	0.2	4
130	Human endogenous retrovirus-enveloped baculoviral DNA vaccines against MERS-CoV and SARS-CoV2. <i>Npj Vaccines</i> , 2021, 6, 37.	2.9	14
131	Impact of pathogen reduction methods on immunological properties of the COVID-19 convalescent plasma. <i>Vox Sanguinis</i> , 2021, 116, 665-672.	0.7	13
132	Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines. <i>Diagnostics</i> , 2021, 11, 579.	1.3	114
133	Blockers of the SARS-CoV-2 3a Channel Identified by Targeted Drug Repurposing. <i>Viruses</i> , 2021, 13, 532.	1.5	18
134	Current progress and challenges in the design and development of a successful COVID-19 vaccine. <i>Fundamental Research</i> , 2021, 1, 139-150.	1.6	19
135	Features of developing SARS-CoV-2 nucleocapsid protein population-based seroprevalence during the first wave of the COVID-19 epidemic in the Russian Federation. <i>Russian Journal of Infection and Immunity</i> , 2021, 11, 297-323.	0.2	30
136	SARS-CoV-2 vaccine ChAdOx1 nCoV-19 infection of human cell lines reveals low levels of viral backbone gene transcription alongside very high levels of SARS-CoV-2 S glycoprotein gene transcription. <i>Genome Medicine</i> , 2021, 13, 43.	3.6	44
137	Frontrunners in the race to develop a SARS-CoV-2 vaccine. <i>Canadian Journal of Microbiology</i> , 2021, 67, 189-212.	0.8	11
139	Broad-Spectrum Anti-coronavirus Vaccines and Therapeutics to Combat the Current COVID-19 Pandemic and Future Coronavirus Disease Outbreaks. <i>Stem Cell Reports</i> , 2021, 16, 398-411.	2.3	18
140	Novel approaches for vaccine development. <i>Cell</i> , 2021, 184, 1589-1603.	13.5	145
141	Covid-19: What do we know about Sputnik V and other Russian vaccines?. <i>BMJ, The</i> , 2021, 372, n743.	3.0	51
142	Risk management strategies and therapeutic modalities to tackle COVID-19/SARS-CoV-2. <i>Journal of Infection and Public Health</i> , 2021, 14, 331-346.	1.9	12
143	Profiles of current COVID-19 vaccines. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 271-283.	1.0	32
144	Potent Neutralization Antibodies Induced by a Recombinant Trimeric Spike Protein Vaccine Candidate Containing PIKA Adjuvant for COVID-19. <i>Vaccines</i> , 2021, 9, 296.	2.1	6
145	COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 313-319.	12.5	103

#	ARTICLE	IF	CITATIONS
146	Advances in gene-based vaccine platforms to address the COVID-19 pandemic. <i>Advanced Drug Delivery Reviews</i> , 2021, 170, 113-141.	6.6	71
147	TREATMENT MODALITIES OF THE COVID-19 PANDEMIC THROUGH REPURPOSED DRUGS AND STATUS OF VACCINES. <i>International Journal of Applied Pharmaceutics</i> , 0, , 48-58.	0.3	4
148	Knowing and combating the enemy: a brief review on SARS-CoV-2 and computational approaches applied to the discovery of drug candidates. <i>Bioscience Reports</i> , 2021, 41, .	1.1	16
149	COVID-19: Insights into Potential Vaccines. <i>Microorganisms</i> , 2021, 9, 605.	1.6	31
150	Immunogenicity of clinically relevant SARS-CoV-2 vaccines in nonhuman primates and humans. <i>Science Advances</i> , 2021, 7, .	4.7	100
151	SARS-CoV-2 vaccination modelling for safe surgery to save lives: data from an international prospective cohort study. <i>British Journal of Surgery</i> , 2021, 108, 1056-1063.	0.1	321
153	Genome-Editing Technologies in Biomedical Research: The Regulatory Conditions for the Development. <i>Kutafin University Law Review</i> , 2021, 8, 115-128.	0.1	0
156	COVID-19 vaccines: Global challenges and prospects forum recommendations. <i>International Journal of Infectious Diseases</i> , 2021, 105, 448-451.	1.5	7
157	The COVID-19 Vaccines: Recent Development, Challenges and Prospects. <i>Vaccines</i> , 2021, 9, 349.	2.1	60
159	The Perception and Attitudes toward COVID-19 Vaccines: A Cross-Sectional Study in Poland. <i>Vaccines</i> , 2021, 9, 382.	2.1	90
160	COVID-19 Vaccines: A Review of the Safety and Efficacy of Current Clinical Trials. <i>Pharmaceuticals</i> , 2021, 14, 406.	1.7	101
161	Immunogenicity of the Ad26.COVS Vaccine for COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1535.	3.8	260
162	A stable platform for the production of virus-like particles pseudotyped with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein. <i>Virus Research</i> , 2021, 295, 198305.	1.1	14
163	An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times. <i>Vaccines</i> , 2021, 9, 433.	2.1	85
164	Nanocarrier vaccines for SARS-CoV-2. <i>Advanced Drug Delivery Reviews</i> , 2021, 171, 215-239.	6.6	66
165	Covid-19 AÄYÄ±larÄ±. SÄ¼leyman Demirel Aoeniversitesi TÄ±p FakÄ¼ltesi Dergisi, 0, , .	0.0	2
166	Immunogenicity and safety of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine in healthy adults: randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trials. <i>Chinese Medical Journal</i> , 2021, 134, 1289-1298.	0.9	49
167	Introduction of Two Prolines and Removal of the Polybasic Cleavage Site Lead to Higher Efficacy of a Recombinant Spike-Based SARS-CoV-2 Vaccine in the Mouse Model. <i>MBio</i> , 2021, 12, .	1.8	62

#	ARTICLE	IF	CITATIONS
168	Strategies for Immunomonitoring after Vaccination and during Infection. <i>Vaccines</i> , 2021, 9, 365.	2.1	12
170	Next-Generation COVID-19 Vaccines Should Take Efficiency of Distribution into Consideration. <i>AAPS PharmSciTech</i> , 2021, 22, 126.	1.5	41
171	Strategy for COVID-19 vaccination in India: the country with the second highest population and number of cases. <i>Npj Vaccines</i> , 2021, 6, 60.	2.9	154
172	Vaccines Developed against COVID-19: a narrative review. <i>Revista Da Associação Médica Brasileira</i> , 2021, 67, 625-631.	0.3	0
174	Vaccines for a healthy future: 21st DCVMN Annual General Meeting 2020 report. <i>Vaccine</i> , 2021, 39, 2479-2488.	1.7	4
175	Developmental Landscape of Potential Vaccine Candidates Based on Viral Vector for Prophylaxis of COVID-19. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 635337.	1.6	22
176	Na ⁺ /K ⁺ -ATPase as a Target of Cardiac Glycosides for the Treatment of SARS-CoV-2 Infection. <i>Frontiers in Pharmacology</i> , 2021, 12, 624704.	1.6	17
177	COVID-19 Vaccines: Current Understanding on Immunogenicity, Safety, and Further Considerations. <i>Frontiers in Immunology</i> , 2021, 12, 669339.	2.2	81
178	Pharmaceutical Aspects and Clinical Evaluation of COVID-19 Vaccines. <i>Immunological Investigations</i> , 2021, 50, 743-779.	1.0	16
180	Polymer-based nano-therapies to combat COVID-19 related respiratory injury: progress, prospects, and challenges. <i>Journal of Biomaterials Science, Polymer Edition</i> , 2021, 32, 1219-1249.	1.9	19
181	Effect of an Adenovirus-Vectored Universal Influenza Virus Vaccine on Pulmonary Pathophysiology in a Mouse Model. <i>Journal of Virology</i> , 2021, 95, .	1.5	7
182	The COVID-19 Vaccine in Clinical Trials: Where Are We Now?. <i>Infectious Diseases & Immunity</i> , 2021, 1, 43-51.	0.2	4
183	Status Report on COVID-19 Vaccines Development. <i>Current Infectious Disease Reports</i> , 2021, 23, 9.	1.3	56
184	The importance of genomic analysis in cracking the coronavirus pandemic. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 547-562.	1.5	14
185	Progress in research on the S protein as the target of COVID-19 vaccines. <i>Expert Review of Vaccines</i> , 2021, 20, 769-772.	2.0	6
186	Vaccines for COVID-19: learning from ten phase II trials to inform clinical and public health vaccination programmes. <i>Public Health</i> , 2021, 193, 57-60.	1.4	10
187	Coronavirus Disease 2019: An Overview of the Complications and Management. , 0, , 1-28.		1
189	Influenza Virus and SARS-CoV-2 Vaccines. <i>Journal of Immunology</i> , 2021, 206, 2509-2520.	0.4	11

#	ARTICLE	IF	CITATIONS
190	Immune response induced by oral administration with a <i>Saccharomyces cerevisiae</i> -based SARS-CoV-2 vaccine in mice. <i>Microbial Cell Factories</i> , 2021, 20, 95.	1.9	23
191	Data discrepancies and substandard reporting of interim data of Sputnik V phase 3 trial. <i>Lancet, The</i> , 2021, 397, 1881-1883.	6.3	26
192	Prime-boost vaccination of mice and rhesus macaques with two novel adenovirus vectored COVID-19 vaccine candidates. <i>Emerging Microbes and Infections</i> , 2021, 10, 1002-1015.	3.0	22
194	Silencing of SARS-CoV-2 with modified siRNA-peptide dendrimer formulation. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2840-2854.	2.7	65
196	Coronavirus disease 2019 (COVID-19) vaccines: A concise review. <i>Oral Diseases</i> , 2022, 28, 2326-2336.	1.5	36
197	Mild Adverse Events of Sputnik V Vaccine in Russia: Social Media Content Analysis of Telegram via Deep Learning. <i>Journal of Medical Internet Research</i> , 2021, 23, e30529.	2.1	27
198	Anti-Coronavirus Vaccines: Past Investigations on SARS-CoV-1 and MERS-CoV, the Approved Vaccines from BioNTech/Pfizer, Moderna, Oxford/AstraZeneca and others under Development Against SARS-CoV-2 Infection. <i>Current Medicinal Chemistry</i> , 2022, 29, 4-18.	1.2	49
199	High-throughput sequencing in vaccine research. <i>Journal of Veterinary Research (Poland)</i> , 2021, 65, 131-137.	0.3	1
201	COVID-19: vaccine's progress. <i>Microbial Biotechnology</i> , 2021, 14, 1246-1257.	2.0	16
202	SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?. <i>Advanced Drug Delivery Reviews</i> , 2021, 172, 314-338.	6.6	75
203	siRNA Therapeutics for the Therapy of COVID-19 and Other Coronaviruses. <i>Molecular Pharmaceutics</i> , 2021, 18, 2105-2121.	2.3	34
204	COVID-19 Vaccines Based on Adenovirus Vectors. <i>Trends in Biochemical Sciences</i> , 2021, 46, 429-430.	3.7	24
205	Management of immune thrombocytopenia during COVID-19 pandemic. <i>Gematologiya i Transfuziologiya</i> , 2021, 66, 20-36.	0.1	1
207	A Synthetic Peptide CTL Vaccine Targeting Nucleocapsid Confers Protection from SARS-CoV-2 Challenge in Rhesus Macaques. <i>Vaccines</i> , 2021, 9, 520.	2.1	28
208	2019 Coronavirus disease (COVID-19): contribution of rheumatology. <i>Terapevticheskii Arkhiv</i> , 2021, 93, .	0.2	6
209	Data discrepancies and substandard reporting of interim data of Sputnik V phase 3 trial – Authors' reply. <i>Lancet, The</i> , 2021, 397, 1883-1884.	6.3	17
210	Covid-19: Sputnik vaccine rockets, thanks to Lancet boost. <i>BMJ, The</i> , 2021, 373, n1108.	3.0	15
211	Cutaneous adverse effects of the available COVID-19 vaccines. <i>Clinics in Dermatology</i> , 2021, 39, 523-531.	0.8	69

#	ARTICLE	IF	CITATIONS
212	Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2. <i>Npj Vaccines</i> , 2021, 6, 74.	2.9	198
214	Simultaneous Evaluation of a Vaccine Component Microheterogeneity and Conformational Integrity Using Native Mass Spectrometry and Limited Charge Reduction. <i>Journal of the American Society for Mass Spectrometry</i> , 2021, 32, 1631-1637.	1.2	8
215	On the road to ending the COVID-19 pandemic: Are we there yet?. <i>Virology</i> , 2021, 557, 70-85.	1.1	38
216	COVID-19 vaccine decisions: considering the choices and opportunities. <i>Microbes and Infection</i> , 2021, 23, 104811.	1.0	17
217	Efficacy and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. <i>Vaccines</i> , 2021, 9, 467.	2.1	228
218	Understanding Post Entry Sorting of Adenovirus Capsids; A Chance to Change Vaccine Vector Properties. <i>Viruses</i> , 2021, 13, 1221.	1.5	9
219	Comparison and Analysis of Neutralizing Antibody Levels in Serum after Inoculating with SARS-CoV-2, MERS-CoV, or SARS-CoV Vaccines in Humans. <i>Vaccines</i> , 2021, 9, 588.	2.1	12
220	Type-2 Diabetes as a Risk Factor for Severe COVID-19 Infection. <i>Microorganisms</i> , 2021, 9, 1211.	1.6	38
222	COVID-19 vaccines: Frequently asked questions and updated answers. <i>Infectious Diseases Now</i> , 2021, 51, 319-333.	0.7	10
223	Levels of Produced Antibodies after Vaccination with mRNA Vaccine; Effect of Previous Infection with SARS-CoV-2. <i>Journal of Clinical Medicine</i> , 2021, 10, 2842.	1.0	7
224	Key Considerations for the Development of Safe and Effective SARS-CoV-2 Subunit Vaccine: A Peptide-Based Vaccine Alternative. <i>Advanced Science</i> , 2021, 8, e2100985.	5.6	16
225	The Current Status and Challenges in the Development of Vaccines and Drugs against Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-CoV-2). <i>BioMed Research International</i> , 2021, 2021, 1-20.	0.9	13
226	Naturally Occurring Bioactives as Antivirals: Emphasis on Coronavirus Infection. <i>Frontiers in Pharmacology</i> , 2021, 12, 575877.	1.6	18
227	COVID-19 in gastroenterology: Where are we now? Current evidence on the impact of COVID-19 in gastroenterology. <i>United European Gastroenterology Journal</i> , 2021, 9, 750-765.	1.6	18
228	COVID-19 Infection and Circulating Microparticles—Reviewing Evidence as Microthrombogenic Risk Factor for Cerebral Small Vessel Disease. <i>Molecular Neurobiology</i> , 2021, 58, 4188-4215.	1.9	16
229	The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3546-3567.	2.0	152
231	Immunological Approaches to the Treatment of Novel Coronavirus Infection (Review). <i>Sovremennyye Tehnologii V Medicine</i> , 2021, 13, 81.	0.4	4
232	Coronavirus disease 2019 vaccination in transplant recipients. <i>Current Opinion in Infectious Diseases</i> , 2021, 34, 275-287.	1.3	15

#	ARTICLE	IF	CITATIONS
233	Nasal vaccination against SARS-CoV-2: Synergistic or alternative to intramuscular vaccines?. <i>International Journal of Pharmaceutics</i> , 2021, 603, 120686.	2.6	83
234	Gam-COVID-Vac (Sputnik V): a heterologous adenoviral vector-based COVID-19 vaccine. <i>Aging Pathobiology and Therapeutics</i> , 2021, 3, 43-45.	0.3	1
235	What gastroenterologists should know about SARS-CoV 2 vaccine: World Endoscopy Organization perspective. <i>United European Gastroenterology Journal</i> , 2021, 9, 787-796.	1.6	4
237	Towards Goals to Refine Prophylactic and Therapeutic Strategies Against COVID-19 Linked to Aging and Metabolic Syndrome. <i>Cells</i> , 2021, 10, 1412.	1.8	6
240	History and Global Status of the New Coronavirus Covid-2019 and Aspects of Previous Infections of SARS-CoV and MERS-CoV: A Systematic Review. <i>Coronaviruses</i> , 2021, 2, .	0.2	0
241	SARS-CoV-2 and hypertension. <i>Physiological Reports</i> , 2021, 9, e14800.	0.7	11
242	A rational strategy to support approved COVID-19 vaccines prioritization. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 3474-3477.	1.4	4
244	Adaptation of the MTT assay for detection of neutralizing antibodies against the SARS-CoV-2 virus. <i>Zhurnal Mikrobiologii Epidemiologii I Immunobiologii</i> , 2021, 98, 253-265.	0.3	10
246	Coronavirus Disease 2019 (COVID-19) and Immune-mediated Rheumatic Diseases. Recommendations of the Association of Rheumatologists of Russia. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2021, 59, 239-254.	0.2	40
247	Current vaccine technology with an emphasis on recombinant measles virus as a new perspective for vaccination against SARS-CoV-2. <i>Euro-Mediterranean Journal for Environmental Integration</i> , 2021, 6, 61.	0.6	0
248	Synthetic Peptides That Antagonize the Angiotensin-Converting Enzyme-2 (ACE-2) Interaction with SARS-CoV-2 Receptor Binding Spike Protein. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 2836-2847.	2.9	22
249	Evaluation of the safety profile of COVID-19 vaccines: a rapid review. <i>BMC Medicine</i> , 2021, 19, 173.	2.3	156
250	COVID-19 vaccines: concerns beyond protective efficacy and safety. <i>Expert Review of Vaccines</i> , 2021, 20, 1013-1025.	2.0	56
251	Recent updates on immunological, pharmacological, and alternative approaches to combat COVID-19. <i>Inflammopharmacology</i> , 2021, 29, 1331-1346.	1.9	7
252	Antiviral Activity of Benzylamine Hydrochloride against SARS-CoV-2 in vitro Model. <i>Epidemiologiya I Vaktsinoprofilaktika</i> , 2021, 20, 83-90.	0.2	1
253	A Comprehensive Review of COVID-19 Virology, Vaccines, Variants, and Therapeutics. <i>Current Medical Science</i> , 2021, 41, 1037-1051.	0.7	136
254	A "mix and match" approach to SARS-CoV-2 vaccination. <i>Nature Medicine</i> , 2021, 27, 1510-1511.	15.2	45
255	Antiviral Activity of Influenza A Virus Defective Interfering Particles against SARS-CoV-2 Replication In Vitro through Stimulation of Innate Immunity. <i>Cells</i> , 2021, 10, 1756.	1.8	19

#	ARTICLE	IF	CITATIONS
256	Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC:) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50	2.1	94
257	Pharmacological interventions for COVID-19: a systematic review of observational studies and clinical trials. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 1219-1244.	2.0	6
258	Current Perspectives in the Discovery of Newer Medications Against the Outbreak of COVID-19. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 648232.	1.6	1
259	SARS-CoV-2 vaccination in patients with inflammatory bowel disease. <i>GastroHep</i> , 2021, 3, 212-228.	0.3	7
260	Human Coronaviruses: Counteracting the Damage by Storm. <i>Viruses</i> , 2021, 13, 1457.	1.5	5
261	Genetic and Chemical Capsid Modifications of Adenovirus Vectors to Modulate Vector-Host Interactions. <i>Viruses</i> , 2021, 13, 1300.	1.5	9
262	Influence of HLA Class II Polymorphism on Predicted Cellular Immunity Against SARS-CoV-2 at the Population and Individual Level. <i>Frontiers in Immunology</i> , 2021, 12, 669357.	2.2	7
263	An Appraisal of the Current Scenario in Vaccine Research for COVID-19. <i>Viruses</i> , 2021, 13, 1397.	1.5	6
264	A Novel Vaccine Selection Decision-Making Model (VSDMM) for COVID-19. <i>Vaccines</i> , 2021, 9, 718.	2.1	18
265	India's pragmatic vaccination strategy against COVID-19: a mathematical modelling-based analysis. <i>BMJ Open</i> , 2021, 11, e048874.	0.8	15
267	Modification of the Spike Protein for Vaccines against Enveloped RNA Viruses. <i>Molecular Biology</i> , 2021, 55, 538-547.	0.4	2
268	Mounting evidence suggests Sputnik COVID vaccine is safe and effective. <i>Nature</i> , 2021, 595, 339-340.	13.7	57
269	Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	56
270	Virus Induced Lymphocytes (VIL) as a novel viral antigen-specific T cell therapy for COVID-19 and potential future pandemics. <i>Scientific Reports</i> , 2021, 11, 15295.	1.6	5
271	Are We Paving the Way to Dig Out of the "Pandemic Hole"? A Narrative Review on SARS-CoV-2 Vaccination: From Animal Models to Human Immunization. <i>Medical Sciences (Basel, Switzerland)</i> , 2021, 9, 53.	1.3	1
272	Cancer Cell-specific Transfection of hCas9 Gene Using Ad5F35 Vector. <i>Anticancer Research</i> , 2021, 41, 3731-3740.	0.5	3
273	COVID-19 Pathogenesis: From Molecular Pathway to Vaccine Administration. <i>Biomedicines</i> , 2021, 9, 903.	1.4	5
274	An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages. <i>International Immunopharmacology</i> , 2021, 96, 107763.	1.7	35

#	ARTICLE	IF	CITATIONS
276	Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants. <i>Nature Communications</i> , 2021, 12, 4598.	5.8	88
277	Headache Attributed to Vaccination Against COVID-19 (Coronavirus SARS-CoV-2) with the ChAdOx1 nCoV-19 (AZD1222) Vaccine: A Multicenter Observational Cohort Study. <i>Pain and Therapy</i> , 2021, 10, 1309-1330.	1.5	28
278	Negative results of humoral immunity after anti-SARS-CoV-2 vaccination in patient with advanced ovarian cancer treated with maintenance immunotherapy and targeted therapy: a clinical case and $\text{\textcircled{D}}$ literature review. <i>Malignant Tumours</i> , 2021, 11, 5-8.	0.1	0
279	Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. <i>Nature Reviews Immunology</i> , 2021, 21, 475-484.	10.6	434
280	Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action. <i>Npj Vaccines</i> , 2021, 6, 104.	2.9	241
281	Nervous and Muscular Adverse Events after COVID-19 Vaccination: A Systematic Review and Meta-Analysis of Clinical Trials. <i>Vaccines</i> , 2021, 9, 939.	2.1	25
283	Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic. <i>Npj Vaccines</i> , 2021, 6, 97.	2.9	175
284	Opinion: A serious issue with the standardization of the adenovirus-based COVID-19 vaccines?. <i>Archives of Toxicology</i> , 2021, 95, 3137-3139.	1.9	0
285	Antibody Responses to Natural SARS-CoV-2 Infection or after COVID-19 Vaccination. <i>Vaccines</i> , 2021, 9, 910.	2.1	50
286	Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. <i>Lancet Infectious Diseases</i> , 2021, 21, 1107-1119.	4.6	345
288	Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: A randomized, double-blind, placebo-controlled, phase 1/2 trial. <i>EClinicalMedicine</i> , 2021, 38, 101010.	3.2	28
289	The challenge of structural heterogeneity in the native mass spectrometry studies of the SARS-CoV-2 spike protein interactions with its host cell-surface receptor. <i>Analytical and Bioanalytical Chemistry</i> , 2021, 413, 7205-7214.	1.9	9
290	COVID-19 Vaccine, TRIPS, and Global Health Diplomacy: India's Role at the WTO Platform. <i>BioMed Research International</i> , 2021, 2021, 1-8.	0.9	33
291	Accelerated COVID-19 vaccine development: milestones, lessons, and prospects. <i>Immunity</i> , 2021, 54, 1636-1651.	6.6	165
292	COVID-19 Vaccines in Patients with Maintenance Hemodialysis. <i>Journal of Personalized Medicine</i> , 2021, 11, 789.	1.1	14
293	Sputnik V vaccine elicits seroconversion and neutralizing capacity to SARS-CoV-2 after a single dose. <i>Cell Reports Medicine</i> , 2021, 2, 100359.	3.3	62
294	SARS-CoV-2 vaccines are the biggest medical research project of the 21st century. <i>Current Opinion in Virology</i> , 2021, 49, 52-57.	2.6	12
295	Promising Technologies in the Field of Helminth Vaccines. <i>Frontiers in Immunology</i> , 2021, 12, 711650.	2.2	24

#	ARTICLE	IF	CITATIONS
296	Immunogenicity of Low-Dose Prime-Boost Vaccination of mRNA Vaccine CV07050101 in Non-Human Primates. <i>Viruses</i> , 2021, 13, 1645.	1.5	8
298	An Overview of Vaccines against SARS-CoV-2 in the COVID-19 Pandemic Era. <i>Pathogens</i> , 2021, 10, 1030.	1.2	33
300	Perioperative Coronavirus Vaccinationâ€”Timing and Implications: A Guidance Document. <i>Annals of Thoracic Surgery</i> , 2021, 112, 1707-1715.	0.7	14
301	ROCCA observational study: Early results on safety of Sputnik V vaccine (Gam-COVID-Vac) in the Republic of San Marino using active surveillance. <i>EClinicalMedicine</i> , 2021, 38, 101027.	3.2	39
302	Adverse events related to COVID-19 vaccines: the need to strengthen pharmacovigilance monitoring systems. <i>Drugs and Therapy Perspectives</i> , 2021, 37, 376-382.	0.3	30
303	Impact of Prior Infection on Severe Acute Respiratory Syndrome Coronavirus 2 Transmission in Syrian Hamsters. <i>Frontiers in Microbiology</i> , 2021, 12, 722178.	1.5	5
306	Essential considerations during vaccine design against COVID-19 and review of pioneering vaccine candidate platforms. <i>International Immunopharmacology</i> , 2021, 97, 107679.	1.7	9
307	Predictive analysis of COVID-19 eradication with vaccination in India, Brazil, and U.S.A. <i>Infection, Genetics and Evolution</i> , 2021, 92, 104834.	1.0	16
308	The Efficacy of COVID-19 Vaccines in Chronic Kidney Disease and Kidney Transplantation Patients: A Narrative Review. <i>Vaccines</i> , 2021, 9, 885.	2.1	57
309	Comparing Results of Five SARS-CoV-2 Antibody Assays Before and After the First Dose of ChAdOx1 nCoV-19 Vaccine among Health Care Workers. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0110521.	1.8	21
310	Cutaneous and hypersensitivity reactions associated with COVID-19 vaccinationâ€”a narrative review. <i>Wiener Medizinische Wochenschrift</i> , 2021, , 1.	0.5	11
311	AACC Practical Recommendations for Implementing and Interpreting SARS-CoV-2 Emergency Use Authorization and Laboratory-Developed Test Serologic Testing in Clinical Laboratories. <i>Clinical Chemistry</i> , 2021, 67, 1188-1200.	1.5	20
314	Shell-mediated phagocytosis to reshape viral-vectored vaccine-induced immunity. <i>Biomaterials</i> , 2021, 276, 121062.	5.7	12
315	B cell depletion in immune-mediated rheumatic diseases and coronavirus disease 2019 (COVID-19). <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2021, 59, 384-393.	0.2	12
316	Anti-COVID-19 Vaccination in Patients with Autoimmune-Autoinflammatory Disorders and Primary/Secondary Immunodeficiencies: The Position of the Task Force on Behalf of the Italian Immunological Societies. <i>Biomedicines</i> , 2021, 9, 1163.	1.4	18
317	Evaluating the effectiveness of control measures in multiple regions during the early phase of the COVID-19 pandemic in 2020. <i>Biosafety and Health</i> , 2021, 3, 264-275.	1.2	11
318	A Self-Biomaterialized Novel Adenovirus Vectored COVID-19 Vaccine for Boosting Immunization of Mice. <i>Virologica Sinica</i> , 2021, 36, 1113-1123.	1.2	11
319	Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. <i>Lancet, The</i> , 2021, 398, 856-869.	6.3	430

#	ARTICLE	IF	CITATIONS
320	Heterologous prime-boost regimens with HAdV-5 and NDV vectors elicit stronger immune responses to Ebola virus than homologous regimens in mice. <i>Archives of Virology</i> , 2021, 166, 3333-3341.	0.9	5
321	COVID-19 Vaccine: A Way Out of Crisis. , 0, , .		0
322	Prospective Cohort Study of the Kinetics of Specific Antibodies to SARS-CoV-2 Infection and to Four SARS-CoV-2 Vaccines Available in Serbia, and Vaccine Effectiveness: A 3-Month Interim Report. <i>Vaccines</i> , 2021, 9, 1031.	2.1	16
323	How the Global COVID-19 Pandemic Brought Drug and Vaccine Development into the Public Mainstream. <i>Pharmaceutical Medicine</i> , 2021, 35, 287-295.	1.0	1
325	Immunological and pathological outcomes of SARS-CoV-2 challenge following formalin-inactivated vaccine in ferrets and rhesus macaques. <i>Science Advances</i> , 2021, 7, eabg7996.	4.7	20
326	Key points to keep in mind related to COVID-19 vaccines in people with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 54, 103142.	0.9	1
327	A comprehensive analysis of the efficacy and safety of COVID-19 vaccines. <i>Molecular Therapy</i> , 2021, 29, 2794-2805.	3.7	105
328	Emerging SARS-CoV-2 Variants of Concern (VOCs): An Impending Global Crisis. <i>Biomedicines</i> , 2021, 9, 1303.	1.4	87
329	Prenatal care providers' perceptions of the SARS-Cov-2 vaccine for themselves and for pregnant women. <i>PLoS ONE</i> , 2021, 16, e0256080.	1.1	12
330	Immunogenicity and protective efficacy of an intranasal live-attenuated vaccine against SARS-CoV-2. <i>IScience</i> , 2021, 24, 102941.	1.9	39
331	The Immune Response to SARS-CoV-2 and Variants of Concern. <i>Viruses</i> , 2021, 13, 1911.	1.5	18
332	An AAV-based, room-temperature-stable, single-dose COVID-19 vaccine provides durable immunogenicity and protection in non-human primates. <i>Cell Host and Microbe</i> , 2021, 29, 1437-1453.e8.	5.1	53
333	Universally Immune: How Infection Permissive Next Generation Influenza Vaccines May Affect Population Immunity and Viral Spread. <i>Viruses</i> , 2021, 13, 1779.	1.5	5
334	Protective Efficacy of Rhesus Adenovirus COVID-19 Vaccines against Mouse-Adapted SARS-CoV-2. <i>Journal of Virology</i> , 2021, 95, e0097421.	1.5	12
335	COVID-19: Post-vaccine Smell and Taste Disorders: Report of 6 Cases. <i>Ear, Nose and Throat Journal</i> , 2024, 103, NP104-NP107.	0.4	26
336	Vaccinia virus-based vaccines confer protective immunity against SARS-CoV-2 virus in Syrian hamsters. <i>PLoS ONE</i> , 2021, 16, e0257191.	1.1	19
338	Humoral and cellular immunity and the safety of COVID-19 vaccines: a summary of data published by 21 May 2021. <i>International Immunology</i> , 2021, 33, 529-540.	1.8	28
339	COVID-19 Animal Models and Vaccines: Current Landscape and Future Prospects. <i>Vaccines</i> , 2021, 9, 1082.	2.1	8

#	ARTICLE	IF	CITATIONS
340	Changes in severity, mortality, and virus genome among a Spanish cohort of patients hospitalized with SARS-CoV-2. <i>Scientific Reports</i> , 2021, 11, 18844.	1.6	10
341	Organizational aspects of vaccination against a new coronavirus infection. <i>Nacional Zdravoohranenie</i> , 2021, 2, 5-11.	0.3	2
342	COVID-19 Pandemic and Vaccines Update on Challenges and Resolutions. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 690621.	1.8	60
343	Safety and immunogenicity of a QazCovid-in [®] inactivated whole-virion vaccine against COVID-19 in healthy adults: A single-centre, randomised, single-blind, placebo-controlled phase 1 and an open-label phase 2 clinical trials with a 6 months follow-up in Kazakhstan. <i>EClinicalMedicine</i> , 2021, 39, 101078.	3.2	37
344	SARS-CoV-2 (Covid-19) vaccines structure, mechanisms and effectiveness: A review. <i>International Journal of Biological Macromolecules</i> , 2021, 188, 740-750.	3.6	83
345	Controversy surrounding the Sputnik V vaccine. <i>Respiratory Medicine</i> , 2021, 187, 106569.	1.3	28
346	Effectiveness of the first component of Gam-COVID-Vac (Sputnik V) on reduction of SARS-CoV-2 confirmed infections, hospitalisations and mortality in patients aged 60-79: a retrospective cohort study in Argentina. <i>EClinicalMedicine</i> , 2021, 40, 101126.	3.2	60
347	Administration of COVID-19 vaccines in immunocompromised patients. <i>International Immunopharmacology</i> , 2021, 99, 108021.	1.7	51
348	COVID-19 pandemics Stage II – Energy and environmental impacts of vaccination. <i>Renewable and Sustainable Energy Reviews</i> , 2021, 150, 111400.	8.2	65
350	A focused review on technologies, mechanisms, safety, and efficacy of available COVID-19 vaccines. <i>International Immunopharmacology</i> , 2021, 100, 108162.	1.7	65
351	A nanoenzyme linked immunochromatographic sensor for rapid and quantitative detection of SARS-CoV-2 nucleocapsid protein in human blood. <i>Sensors and Actuators B: Chemical</i> , 2021, 349, 130718.	4.0	34
352	Carbohydrates-based diagnosis, prophylaxis and treatment of infectious diseases: Special emphasis on COVID-19. <i>Carbohydrate Polymer Technologies and Applications</i> , 2021, 2, 100052.	1.6	7
353	E484K mutation in SARS-CoV-2 RBD enhances binding affinity with hACE2 but reduces interactions with neutralizing antibodies and nanobodies: Binding free energy calculation studies. <i>Journal of Molecular Graphics and Modelling</i> , 2021, 109, 108035.	1.3	52
354	Operation Warp Speed: Projects responding to the COVID-19 pandemic. <i>Project Leadership and Society</i> , 2021, 2, 100019.	1.8	29
355	Comparative Analysis of SARS-CoV-2-Specific B Cell and Humoral Responses Elicited by Sputnik V in Naïve and COVID-19-Recovered Vaccine Recipients. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
356	The COVID-19 vaccine: A race nearing the finish line. <i>Apollo Medicine</i> , 2021, .	0.0	1
357	COVID-19 vaccine: an overview of the progression and current use. <i>İstanbul Kuzey Klinikleri</i> , 2021, 8, 529-536.	0.1	0
358	Recombinant chimpanzee adenovirus AdC7 expressing dimeric tandem-repeat spike protein RBD protects mice against COVID-19. <i>Emerging Microbes and Infections</i> , 2021, 10, 1574-1588.	3.0	18

#	ARTICLE	IF	CITATIONS
359	Overview of approved and upcoming vaccines for SARS-CoV-2: a living review. Oxford Open Immunology, 2021, 2, iqab010.	1.2	18
360	Peripheral T cell lymphopenia in COVID-19: potential mechanisms and impact. Immunotherapy Advances, 2021, 1, .	1.2	14
361	SARS-CoV-2 Antibody Response Following SPUTNIK V Vaccination in Healthcare Workers From a Hospital in Argentina: Preliminary Results. SSRN Electronic Journal, 0, , .	0.4	2
362	What We Do Know and Do Not Yet Know about COVID-19 Vaccines as of the Beginning of the Year 2021. Journal of Korean Medical Science, 2021, 36, e54.	1.1	24
363	Current State of the First COVID-19 Vaccines. Vaccines, 2021, 9, 30.	2.1	64
364	T cell response to SARS-CoV-2 infection in humans: A systematic review. PLoS ONE, 2021, 16, e0245532.	1.1	228
365	A comprehensive overview of vaccines developed for pandemic viral pathogens over the past two decades including those in clinical trials for the current novel SARS-CoV-2. RSC Advances, 2021, 11, 20006-20035.	1.7	6
366	A Bioelectromagnetic Proposal Approaching the Complex Challenges of COVID-19. Open Journal of Biophysics, 2021, 11, 1-67.	0.7	1
367	Current Status of COVID-19 Vaccine Development: Focusing on Antigen Design and Clinical Trials on Later Stages. Immune Network, 2021, 21, e4.	1.6	26
368	Sex Differences in Immunity: Implications for the Development of Novel Vaccines Against Emerging Pathogens. Frontiers in Immunology, 2020, 11, 601170.	2.2	33
369	Topical issues of diagnostics, examination and treatment of patients with COVID-19-associated pneumonia in different countries and continents. Meditsinskiy Sovet, 2021, , 96-102.	0.1	15
370	Advances in vaccination to combat pandemic outbreaks. , 2021, , 123-137.		1
371	Adenoviral Vectors as Vaccines for Emerging Avian Influenza Viruses. Frontiers in Immunology, 2020, 11, 607333.	2.2	21
372	The T-cell response to SARS-CoV-2: kinetic and quantitative aspects and the case for their protective role. Oxford Open Immunology, 2021, 2, .	1.2	59
373	Researchers highlight "questionable" data in Russian coronavirus vaccine trial results. Nature, 2020, 585, 493-493.	13.7	5
374	Human species D adenovirus hexon capsid protein mediates cell entry through a direct interaction with CD46. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	45
375	SARS-CoV-2 Serologic Assay Needs for the Next Phase of the US COVID-19 Pandemic Response. Open Forum Infectious Diseases, 2021, 8, ofaa555.	0.4	66
382	COVID-19 vaccines - are we there yet?. Australian Prescriber, 2021, 44, 19-25.	0.5	15

#	ARTICLE	IF	CITATIONS
383	Experience in Studying Seroprevalence to SARS-CoV-2 Virus in the Population of the Irkutsk Region during COVID-19 Outbreak. <i>Problemy Osobo Opasnykh Infektsii</i> , 2020, , 106-113.	0.2	19
384	Nature Of, Immune Reaction and Side Effects of COVID-19 Vaccines: Synthesis of Information from Ten Phase II Trials for Planning Vaccination Programmes. <i>SSRN Electronic Journal</i> , 0, , .	0.4	3
385	Analysis of Promising Approaches to COVID-19 Vaccine Development. <i>BIOpreparations Prevention Diagnosis Treatment</i> , 2020, 20, 216-227.	0.2	10
386	Russian and International Regulatory Recommendations for the Development and Marketing Authorisation of COVID-19 Vaccines in the Context of the Pandemic. <i>BIOpreparations Prevention Diagnosis Treatment</i> , 2020, 20, 228-244.	0.2	1
387	Vaccines against Covid-19: the Comparative Estimates of Risks in Adenovirus Vectors. <i>Epidemiologiya I Vaktsinoprofilaktika</i> , 2020, 19, 4-17.	0.2	8
388	The Current Status of Drug Repositioning and Vaccine Developments for the COVID-19 Pandemic. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9775.	1.8	40
389	Viral Vector Vaccines against Bluetongue Virus. <i>Microorganisms</i> , 2021, 9, 42.	1.6	14
390	Lead SARS-CoV-2 Candidate Vaccines: Expectations from Phase III Trials and Recommendations Post-Vaccine Approval. <i>Viruses</i> , 2021, 13, 54.	1.5	61
391	Harnessing Cellular Immunity for Vaccination against Respiratory Viruses. <i>Vaccines</i> , 2020, 8, 783.	2.1	13
392	Advances in Oral Subunit Vaccine Design. <i>Vaccines</i> , 2021, 9, 1.	2.1	102
393	Platforms Exploited for SARS-CoV-2 Vaccine Development. <i>Vaccines</i> , 2021, 9, 11.	2.1	17
394	Plant-Based Drugs and Vaccines for COVID-19. <i>Vaccines</i> , 2021, 9, 15.	2.1	34
395	Efficacy and safety of COVID-19 vaccines: a systematic review. <i>Chinese Journal of Contemporary Pediatrics</i> , 2021, 23, 221-228.	0.2	81
397	An updated review on potential therapeutic drug candidates, vaccines and an insight on patents filed for COVID-19. <i>Current Research in Pharmacology and Drug Discovery</i> , 2021, 2, 100063.	1.7	7
398	Optimal Vaccine Roll-Out Strategies with Respect to Social Distancing Measures for SARS-CoV-2 Pandemic. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
399	SARS-CoV-2: Pathogenic Mechanisms and Host Immune Response. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1313, 99-134.	0.8	6
400	Implications for clinical dental practice during the coronavirus disease pandemic: A scoping review. <i>Journal of Prosthodontic Research</i> , 2022, 66, 6-11.	1.1	4
401	Adenoviral vectorâ€¢based platforms for developing effective vaccines to combat respiratory viral infections. <i>Clinical and Translational Immunology</i> , 2021, 10, e1345.	1.7	14

#	ARTICLE	IF	CITATIONS
402	A Single Dose of a Hybrid hAdV5-Based Anti-COVID-19 Vaccine Induces a Long-Lasting Immune Response and Broad Coverage against VOC. <i>Vaccines</i> , 2021, 9, 1106.	2.1	5
403	COVID-19 Vaccines: Adenoviral Vectors. <i>Annual Review of Medicine</i> , 2022, 73, 41-54.	5.0	46
404	Review: Development of SARS-CoV-2 immuno-enhanced COVID-19 vaccines with nano-platform. <i>Nano Research</i> , 2022, 15, 2196-2225.	5.8	8
405	Long Term Immune Response Produced by the SputnikV Vaccine. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11211.	1.8	9
408	Nanotechnology Interventions in the Management of COVID-19: Prevention, Diagnosis and Virus-Like Particle Vaccines. <i>Vaccines</i> , 2021, 9, 1129.	2.1	26
409	WHO International Standard for evaluation of the antibody response to COVID-19 vaccines: call for urgent action by the scientific community. <i>Lancet Microbe</i> , The, 2022, 3, e235-e240.	3.4	108
410	Diverse vaccine platforms safeguarding against SARS-CoV-2 and its variants. <i>Expert Review of Vaccines</i> , 2022, 21, 47-67.	2.0	3
411	Molecular Insights of SARS-CoV-2 Infection and Molecular Treatments. <i>Current Molecular Medicine</i> , 2022, 22, 621-639.	0.6	2
412	COVID-19 Vaccine Platforms: Challenges and Safety Contemplations. <i>Vaccines</i> , 2021, 9, 1196.	2.1	15
413	Susceptibility of Dog, Hamster, and Mouse Cells to the Replication-Competent Adenovirus 11p E1/E3 Green Fluorescence Protein Vector Has Implications for the Selection of Animal Vaccine Models. <i>Frontiers in Microbiology</i> , 2021, 12, 698999.	1.5	1
414	Emerging SARS-CoV-2 Variants: A Review of Its Mutations, Its Implications and Vaccine Efficacy. <i>Vaccines</i> , 2021, 9, 1195.	2.1	90
415	Triple jeopardy in ageing: COVID-19, co-morbidities and inflamm-ageing. <i>Ageing Research Reviews</i> , 2022, 73, 101494.	5.0	11
416	Efficacy, Immunogenicity and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis. <i>Frontiers in Immunology</i> , 2021, 12, 714170.	2.2	145
417	Comparative characteristics of COVID-19 vaccines used for mass immunisation. <i>BIOpreparations Prevention Diagnosis Treatment</i> , 2021, 21, 158-166.	0.2	6
419	A student led computational screening of peptide inhibitors against main protease of SARS-CoV-2. <i>Biochemistry and Molecular Biology Education</i> , 2022, 50, 7-20.	0.5	4
420	Novel therapeutic drug strategies to tackle immune-oncological challenges faced by cancer patients during COVID-19. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1371-1383.	1.1	12
421	Innovative vaccine platforms against infectious diseases: Under the scope of the COVID-19 pandemic. <i>International Journal of Pharmaceutics</i> , 2021, 610, 121212.	2.6	11
422	GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults. <i>Science Translational Medicine</i> , 2022, 14, eabj1996.	5.8	18

#	ARTICLE	IF	CITATIONS
423	Recent Update of COVID-19 Vaccines. <i>Advanced Pharmaceutical Bulletin</i> , 2021, , .	0.6	0
424	Development of synthetic antigen vaccines for COVID-19. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 3855-3870.	1.4	4
425	Assessment of T-cell immunity to SARS-CoV-2 in COVID-19 convalescents and vaccinated subjects, using Tigratest [®] SARS-CoV-2 ELISPOT kit. <i>BIOpreparations Prevention Diagnosis Treatment</i> , 2021, 21, 178-192.	0.2	12
426	Nano-carriers of COVID-19 vaccines: the main pillars of efficacy. <i>Nanomedicine</i> , 2021, 16, 2377-2387.	1.7	8
427	SARS-CoV-2: Current trends in emerging variants, pathogenesis, immune responses, potential therapeutic, and vaccine development strategies. <i>International Immunopharmacology</i> , 2021, 101, 108232.	1.7	14
428	Complete protection by a single-dose skin patch [®] delivered SARS-CoV-2 spike vaccine. <i>Science Advances</i> , 2021, 7, eabj8065.	4.7	31
429	A Strategy for the Rapid Development of a Safe <i>Vibrio cholerae</i> Candidate Vaccine Strain. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11657.	1.8	2
431	Guillain-Barre Syndrome and COVID-19 Vaccine: A Report of Nine Patients. <i>Basic and Clinical Neuroscience</i> , 2021, 12, 703-710.	0.3	24
433	Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity. <i>Cells</i> , 2021, 10, 2949.	1.8	26
436	SARS-CoV-2 immunity and an overview of the COVID-19 vaccines. <i>Medicinski Podmladak</i> , 2021, 72, 20-29.	0.2	3
437	First real-world experience of Gam-COVID-Vac Sputnik V vaccine use. <i>Profilakticheskaya Meditsina</i> , 2021, 24, 53.	0.2	4
438	CORONAVIRUS VACCINE DEVELOPMENT: FROM SARS AND MERS TO COVID-19 (RUSSIAN TRANSLATION). <i>Juvenis Scientia</i> , 2020, 6, 41-80.	0.1	0
439	Prospects of vaccine against COVID-19. <i>Indian Journal of Community Medicine</i> , 2020, 45, 391.	0.2	2
440	Sputnik V Protection from COVID-19 of HIV-Infected Individuals Under Art. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
442	Vaccine-Induced Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response and the Path to Accelerating Development (Determining a Correlate of Protection). <i>Clinics in Laboratory Medicine</i> , 2022, 42, 111-128.	0.7	8
443	Prospects for improving immunoprophylaxis of infectious diseases. <i>Vestnik of Russian Military Medical Academy</i> , 2021, 23, 189-194.	0.1	0
444	SARS-CoV-2 variants and effectiveness of vaccines: a review of current evidence. <i>Epidemiology and Infection</i> , 2021, 149, 1-24.	1.0	43
445	Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in healthy individuals: protocol for a systematic review and meta-analysis. <i>BMJ Open</i> , 2021, 11, e056106.	0.8	2

#	ARTICLE	IF	CITATIONS
446	ASSESSMENT OF POPULATION IMMUNITY TO THE SARS-COV-2 VIRUS AMONG THE POPULATION OF GRODNO. <i>Å½urnal Grodnenskogo Gosudarstvennogo Medicinskogo Universiteta</i> , 2021, 19, 489-495.	0.0	0
452	Efficacy and safety of potential vaccine candidates against coronavirus disease 2019: A systematic review. <i>Journal of Advanced Pharmaceutical Technology and Research</i> , 2021, 12, 215-221.	0.4	2
453	Viral-vectored vaccines against SARS-CoV-2. , 2022, , 115-127.		1
454	Long-term analysis of antibodies elicited by SPUTNIK V: A prospective cohort study in Tucumán, Argentina. <i>The Lancet Regional Health Americas</i> , 2022, 6, 100123.	1.5	21
455	SARS-CoV-2: Overview and Its Impact on Oral Health. <i>Biomedicines</i> , 2021, 9, 1690.	1.4	7
456	Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization. <i>Nature Communications</i> , 2021, 12, 6871.	5.8	147
457	Adenovirus vector-based vaccine for infectious diseases. <i>Drug Metabolism and Pharmacokinetics</i> , 2022, 42, 100432.	1.1	55
458	Ocular Manifestations after Receiving COVID-19 Vaccine: A Systematic Review. <i>Vaccines</i> , 2021, 9, 1404.	2.1	33
459	A Systematic Review on COVID-19 Vaccine Strategies, Their Effectiveness, and Issues. <i>Vaccines</i> , 2021, 9, 1387.	2.1	51
460	Counting on COVID-19 Vaccine: Insights into the Current Strategies, Progress and Future Challenges. <i>Biomedicines</i> , 2021, 9, 1740.	1.4	16
461	Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity. <i>Seminars in Immunology</i> , 2021, 55, 101533.	2.7	72
462	Safety and Seroconversion of Immunotherapies against SARS-CoV-2 Infection: A Systematic Review and Meta-Analysis of Clinical Trials. <i>Pathogens</i> , 2021, 10, 1537.	1.2	19
464	Covid-19 vaccines and variants of concern: A review. <i>Reviews in Medical Virology</i> , 2022, 32, e2313.	3.9	201
465	COVID-19 vaccine confidence and hesitancy among health care workers: A cross-sectional survey from a MERS-CoV experienced nation. <i>PLoS ONE</i> , 2021, 16, e0244415.	1.1	63
466	Prevalence of COVID-19 vaccines (Sputnik V, AZD-1222, and Covaxin) side effects among healthcare workers in Birjand city, Iran. <i>International Immunopharmacology</i> , 2021, 101, 108351.	1.7	36
467	Herd immunity to SARS-CoV-2 among the population of the Republic of Belarus amid the COVID-19 pandemic. <i>Russian Journal of Infection and Immunity</i> , 2021, 11, 887-904.	0.2	9
468	<i>Ex Vivo</i> and <i>In Vivo</i> CD46 Receptor Utilization by Species D Human Adenovirus Serotype 26 (HAdV26). <i>Journal of Virology</i> , 2022, 96, JVI0082621.	1.5	9
469	Battle of COVID-19. <i>Journal of Medical Academics</i> , 2021, 4, 1-4.	0.1	0

#	ARTICLE	IF	CITATIONS
470	Immunomodulation of COVID-19 severity by helminth co-infection: Implications for COVID-19 vaccine efficacy. <i>Immunity, Inflammation and Disease</i> , 2021, , .	1.3	10
471	The intestinal microbiota and improving the efficacy of COVID-19 vaccinations. <i>Journal of Functional Foods</i> , 2021, 87, 104850.	1.6	23
472	Heterologous prime-boost strategies for COVID-19 vaccines. <i>Journal of Travel Medicine</i> , 2021, , .	1.4	37
473	Biotech, Biodefense and COVID-19 Vaccines in Russia's National Security State. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
474	Motivation of COVID-19 Vaccination Among Hospital Employees: A National Survey. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
475	Comprehensive literature review on COVID-19 vaccines and role of SARS-CoV-2 variants in the pandemic. , 2021, 9, 251513552110597.	1.4	15
476	Seroprevalence of SARS-Cov-2 Antibodies in Adults, Arkhangelsk, Russia. <i>Emerging Infectious Diseases</i> , 2022, 28, 463-465.	2.0	3
477	Antibody responses induced by Sputnik V vaccine in individuals previously infected with SARS-CoV-2. <i>The Lancet Regional Health Americas</i> , 2022, 6, 100172.	1.5	0
478	Development of a high-throughput RT-PCR based viral infectivity assay for monitoring the stability of a replicating recombinant Lymphocytic Choriomeningitis viral vector. <i>Journal of Virological Methods</i> , 2022, 301, 114440.	1.0	1
479	Comparative analysis of existing platforms for the development of vaccines against dangerous and extremely dangerous viral infections with pandemic potential. <i>BIOpreparations Prevention Diagnosis Treatment</i> , 2021, 21, 225-233.	0.2	0
480	Approaches to quality control, preclinical and clinical studies of live recombinant viral vector vaccines. <i>BIOpreparations Prevention Diagnosis Treatment</i> , 2021, 21, 212-224.	0.2	0
481	Evaluation of short-term safety of COVID-19 vaccines in patients with multiple sclerosis from Latin America. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021, 7, 205521732110615.	0.5	10
482	Intranasal HD-Ad vaccine protects the upper and lower respiratory tracts of hACE2 mice against SARS-CoV-2. <i>Cell and Bioscience</i> , 2021, 11, 202.	2.1	13
483	La producción y el flujo del conocimiento en la carrera internacional por las vacunas de COVID-19. <i>Foro Internacional</i> , 0, , 47-102.	0.2	2
484	Longitudinal Study after Sputnik V Vaccination Shows Durable SARS-CoV-2 Neutralizing Antibodies and Reduced Viral Variant Escape to Neutralization over Time. <i>MBio</i> , 2022, 13, e0344221.	1.8	19
485	Immune Maturation Effects on Viral Neutralization and Avidity of Hyperimmunized Equine Anti-SARS-CoV-2 Sera. <i>Antibodies</i> , 2022, 11, 3.	1.2	1
486	Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines. <i>Pharmacological Reviews</i> , 2022, 74, 313-339.	7.1	9
487	Interleukin-1 Inhibitors and Vaccination Including COVID-19 in Inflammatory Rheumatic Diseases: A Nonsystematic Review. <i>Frontiers in Immunology</i> , 2021, 12, 734279.	2.2	5

#	ARTICLE	IF	CITATIONS
488	An Outline of Contributing Vaccine Technologies for SARS CoV2 Advancing in Clinical and Preclinical Phase-Trials. <i>Recent Patents on Biotechnology</i> , 2022, 16, 122-143.	0.4	6
489	Covid-19 vaccines production and societal immunization under the serendipity-mindsponge-3D knowledge management theory and conceptual framework. <i>Humanities and Social Sciences Communications</i> , 2022, 9, .	1.3	85
490	COVID-19: Testing Landscape Post-Infection, -Vaccination, and Future Perspectives. <i>Viral Immunology</i> , 2022, 35, 5-14.	0.6	0
491	Cellular Immune Response after Vaccination in Patients with Cancer”Review on Past and Present Experiences. <i>Vaccines</i> , 2022, 10, 182.	2.1	9
492	Long-term dynamics of the levels of anti-SARS-CoV-2 S-protein IgG antibodies in vaccinated individuals. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2022, 20, 3124.	0.4	7
493	Multi-Level Monitoring of Vaccination Adherence of Various Population Groups in the Context of the COVID-19 Pandemic: Problematic Issues. <i>Epidemiologiya I Vaktsinoprofilaktika</i> , 2022, 20, 28-36.	0.2	3
494	Risk Perception and Acceptability of the COVID-19 Vaccine in Nigeria. <i>Turkish Journal of Pharmaceutical Sciences</i> , 2022, 19, 686-693.	0.6	2
495	Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial. <i>Nature Medicine</i> , 2022, 28, 401-409.	15.2	113
496	Boosting of the SARS-CoV-2”Specific Immune Response after Vaccination with Single-Dose Sputnik Light Vaccine. <i>Journal of Immunology</i> , 2022, 208, 1139-1145.	0.4	10
498	Evaluation of the Gam-COVID-Vac and vaccine-induced neutralizing response against SARS-CoV-2 lineage P.1 variant in an Argentinean cohort. <i>Vaccine</i> , 2022, 40, 811-818.	1.7	9
499	Adenovirus-based vaccines and thrombosis in pregnancy: A systematic review and meta-analysis. <i>Clinical Infectious Diseases</i> , 2022, , .	2.9	6
500	Immune responses following the first dose of the Sputnik V (Gam-COVID-Vac). <i>Scientific Reports</i> , 2022, 12, 1727.	1.6	11
501	Allergies and COVID”19 vaccines: An ENDA/EAACI Position paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2292-2312.	2.7	55
502	COVID-19 Compulsory Vaccination: Legal and Bioethical Controversies. <i>Frontiers in Medicine</i> , 2022, 9, 821522.	1.2	12
503	A comprehensive review on COVID-19 vaccines: development, effectiveness, adverse effects, distribution and challenges. <i>VirusDisease</i> , 2022, 33, 1-22.	1.0	47
504	Immunogenicity of BNT162b2, BBIBP-CorV and Gam-COVID-Vac vaccines and immunity after natural SARS-CoV-2 infection”A comparative study from Novi Sad, Serbia. <i>PLoS ONE</i> , 2022, 17, e0263468.	1.1	33
505	The SARS-CoV-2 mutations versus vaccine effectiveness: New opportunities to new challenges. <i>Journal of Infection and Public Health</i> , 2022, 15, 228-240.	1.9	122
506	Vaccination policy and trust. <i>Economic Modelling</i> , 2022, 108, 105773.	1.8	13

#	ARTICLE	IF	CITATIONS
507	COVID-19 vaccine therapeutic trials review: published results and registered protocols. <i>Journal of Global Health Reports</i> , 0, 5, .	1.0	0
509	Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2022, 2022, 1-16.	0.7	2
510	Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines. <i>Annals of Medicine</i> , 2022, 54, 524-540.	1.5	225
511	Data and distrust hamper Russia's vaccination programme. <i>BMJ</i> , The, 2022, 376, o321.	3.0	1
512	Neurological Immune-Related Adverse Events After COVID-19 Vaccination: A Systematic Review. <i>Journal of Clinical Pharmacology</i> , 2022, 62, 291-303.	1.0	23
513	A review of the safety and efficacy of current COVID-19 vaccines. <i>Frontiers of Medicine</i> , 2022, 16, 39-55.	1.5	19
514	The efficacy and effectiveness of the COVID-19 vaccines in reducing infection, severity, hospitalization, and mortality: a systematic review. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-20.	1.4	163
516	An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 44.	7.1	31
517	Analytical characterization of the SARS-CoV-2 EURM-017 reference material. <i>Clinical Biochemistry</i> , 2022, 101, 19-25.	0.8	5
518	Immunogenicity and Safety of a 3-Dose Regimen of a SARS-CoV-2 Inactivated Vaccine in Adults: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. <i>Journal of Infectious Diseases</i> , 2022, 225, 1701-1709.	1.9	9
521	Russian and Chinese vaccines. , 2022, , 71-77.		0
522	Biotechnology strategies for the development of novel therapeutics and vaccines against the novel COVID-19 pandemic. , 2022, , 205-226.		0
523	Drummondin E and Flinderole B are potential inhibitors of RNA-dependent RNA polymerase of SARS-CoV-2: an in silico study. <i>Biotechnologia</i> , 2022, 103, 53-70.	0.3	1
524	A Meta-Analysis on the Safety and Immunogenicity of Covid-19 Vaccines. <i>Journal of Primary Care and Community Health</i> , 2022, 13, 215013192210892.	1.0	21
525	An Update on the Status of Vaccine Development for SARS-CoV-2 Including Variants. <i>Practical Considerations for COVID-19 Special Populations. Clinical and Applied Thrombosis/Hemostasis</i> , 2022, 28, 107602962110566.	0.7	13
526	Fighting Fire with Fire: Immunogenicity of Viral Vected Vaccines against COVID-19. <i>Viruses</i> , 2022, 14, 380.	1.5	4
527	E4orf1 Suppresses E1B-Deleted Adenovirus Vaccine-Induced Immune Responses. <i>Vaccines</i> , 2022, 10, 295.	2.1	2
528	Self-Assembled Particles Combining SARS-CoV-2 RBD Protein and RBD DNA Vaccine Induce Synergistic Enhancement of the Humoral Response in Mice. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2188.	1.8	15

#	ARTICLE	IF	CITATIONS
529	Novel Strategies of Immunization against COVID-19. <i>Journal of Pure and Applied Microbiology</i> , 2022, 16, 35-49.	0.3	0
531	Classical and Next-Generation Vaccine Platforms to SARS-CoV-2: Biotechnological Strategies and Genomic Variants. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 2392.	1.2	11
532	mRNA vaccine-induced antibodies more effective than natural immunity in neutralizing SARS-CoV-2 and its high affinity variants. <i>Scientific Reports</i> , 2022, 12, 2628.	1.6	34
533	Vaccine Candidate Against COVID-19 Based on Structurally Modified Plant Virus as an Adjuvant. <i>Frontiers in Microbiology</i> , 2022, 13, 845316.	1.5	8
534	Side effects of COVID-19 vaccines: a systematic review and meta-analysis protocol of randomised trials. <i>BMJ Open</i> , 2022, 12, e050278.	0.8	21
535	Immunogenic and reactogenic efficacy of Covaxin and Covishield: a comparative review. <i>Immunologic Research</i> , 2022, 70, 289-315.	1.3	34
536	Seropositivity of SARS-CoV-2 in the Population of Kazakhstan: A Nationwide Laboratory-Based Surveillance. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 2263.	1.2	3
537	Analysis of the effectiveness of vaccination against COVID-19 based on real-world data in St. Petersburg. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2022, , 80-84.	0.2	3
538	The efficient development of a novel recombinant adenovirus zoster vaccine perfusion production process. <i>Vaccine</i> , 2022, 40, 2036-2043.	1.7	4
539	Immunogenic Epitope-Based Vaccine Prediction from Surface Glycoprotein of MERS-CoV by Deploying Immunoinformatics Approach. <i>International Journal of Peptide Research and Therapeutics</i> , 2022, 28, 77.	0.9	5
541	Post COVID-19 vaccination Guillain-Barre syndrome: three cases. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-5.	1.4	16
542	A systematic review on mucocutaneous presentations after COVID-19 vaccination and expert recommendations about vaccination of important immune-mediated dermatologic disorders. <i>Dermatologic Therapy</i> , 2022, 35, e15461.	0.8	31
543	A tandem-repeat dimeric RBD protein-based covid-19 vaccine zf2001 protects mice and nonhuman primates. <i>Emerging Microbes and Infections</i> , 2022, 11, 1058-1071.	3.0	63
544	Early Effectiveness of Four SARS-CoV-2 Vaccines in Preventing COVID-19 among Adults Aged ≥60 Years in Vojvodina, Serbia. <i>Vaccines</i> , 2022, 10, 389.	2.1	15
546	Probable treatment options for Covid-19: A brief review. <i>IP International Journal of Comprehensive and Advanced Pharmacology</i> , 2022, 7, 17-26.	0.1	0
547	Selection and Validation of siRNAs Preventing Uptake and Replication of SARS-CoV-2. <i>Frontiers in Bioengineering and Biotechnology</i> , 2022, 10, 801870.	2.0	13
548	Antibody responses to Sputnik Vaccination in naïve and COVID 19-recovered vaccine recipients, India. <i>Journal of Travel Medicine</i> , 2022, 29, .	1.4	2
549	Covid-19: Ukraine conflict calls Russia's vaccine diplomacy into question. <i>BMJ</i> , The, 2022, 376, o626.	3.0	4

#	ARTICLE	IF	CITATIONS
550	On the Issue of Evaluating the Effectiveness of Vaccination of Employees of Medical Organizations against COVID-19. <i>Epidemiologiya i Vaktsinoprofilaktika</i> , 2022, 21, 61-66.	0.2	8
551	Various vaccine platforms in the field of COVID-19. <i>Beni-Suef University Journal of Basic and Applied Sciences</i> , 2022, 11, 35.	0.8	10
553	Covid-19 Vaccines Available in India. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2022, 25, 2391-2397.	0.6	3
555	Human adenovirus type 26 basic biology and its usage as vaccine vector. <i>Reviews in Medical Virology</i> , 2022, 32, e2338.	3.9	4
557	Headache onset after vaccination against SARS-CoV-2: a systematic literature review and meta-analysis. <i>Journal of Headache and Pain</i> , 2022, 23, 41.	2.5	43
558	Oral SARS-CoV-2 Spike Protein Recombinant Yeast Candidate Prompts Specific Antibody and Gut Microbiota Reconstruction in Mice. <i>Frontiers in Microbiology</i> , 2022, 13, 792532.	1.5	11
559	Sputnik V protection from COVID-19 in people living with HIV under antiretroviral therapy. <i>EClinicalMedicine</i> , 2022, 46, 101360.	3.2	17
560	Development of COVID 19 vaccine: A summarized review on global trials, efficacy, and effectiveness on variants. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2022, 16, 102482.	1.8	9
561	mRNA- and Adenovirus-Based Vaccines against SARS-CoV-2 in HIV-Positive People. <i>Viruses</i> , 2022, 14, 748.	1.5	11
562	From Bench Side to Bed-Travelling on a Road to Get a Safe and Effective Vaccine against COVID-19, Day to Save the Life. <i>Recent Patents on Biotechnology</i> , 2022, 16, 2-5.	0.4	4
563	Outcomes of single dose COVID-19 vaccines: Eight month follow-up of a large cohort in Saudi Arabia. <i>Journal of Infection and Public Health</i> , 2022, 15, 573-577.	1.9	7
564	Safety and immunogenicity of an inactivated virus particle vaccine for SARS-CoV-2, BIV1-CovIran: findings from double-blind, randomised, placebo-controlled, phase I and II clinical trials among healthy adults. <i>BMJ Open</i> , 2022, 12, e056872.	0.8	12
565	A global survey in the developmental landscape of possible vaccination strategies for COVID-19. <i>Clinical Immunology</i> , 2022, 237, 108958.	1.4	11
566	Immunogenic epitope panel for accurate detection of non-cross-reactive T cell response to SARS-CoV-2. <i>JCI Insight</i> , 2022, 7, .	2.3	13
567	Mutation hotspots of SARS-CoV-2 RNA motifs conserved in betacoronaviruses. <i>Journal of Physics: Conference Series</i> , 2021, 2099, 012037.	0.3	0
568	Immunogenic Properties of the DNA Construct Encoding the Receptor-Binding Domain of the SARS-CoV-2 Spike Protein. <i>Molecular Biology</i> , 2021, 55, 889-898.	0.4	12
569	Molecular and Clinical Aspects of COVID-19 Vaccines and Other Therapeutic Interventions Apropos Emerging Variants of Concern. <i>Frontiers in Pharmacology</i> , 2021, 12, 778219.	1.6	0
570	Combinatorial Viral Vector-Based and Live Attenuated Vaccines without an Adjuvant to Generate Broader Immune Responses to Effectively Combat Pneumonic Plague. <i>MBio</i> , 2021, 12, e0322321.	1.8	6

#	ARTICLE	IF	CITATIONS
571	Immunogenicity and safety of adenovirus-based vector vaccines for COVID-19: a systematic review and meta-analysis. <i>Medical Journal of Indonesia</i> , 2022, 30, 264-78.	0.2	1
572	Vaccination Against COVID-19: Emerging Issues and Future Prospects. <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , 2021, 76, 652-660.	0.2	1
573	SARS-CoV-2 ferritin nanoparticle vaccine induces robust innate immune activity driving polyfunctional spike-specific T cell responses. <i>Npj Vaccines</i> , 2021, 6, 151.	2.9	36
574	Vaccination against new coronavirus infection in patients with cardiovascular and autoimmune diseases. <i>Complex Issues of Cardiovascular Diseases</i> , 2021, 10, 112-121.	0.3	1
575	Heterologous prime-boost immunizations with chimpanzee adenoviral vectors elicit potent and protective immunity against SARS-CoV-2 infection. <i>Cell Discovery</i> , 2021, 7, 123.	3.1	10
576	Criteria for judging the immune markers of COVID-19 disease vaccines. <i>MedComm</i> , 2022, 3, 1-12.	3.1	3
578	Results of the work of the Military medical academy research institute of novel coronavirus infection problems through 2020-2021. <i>Vestnik of Russian Military Medical Academy</i> , 2021, 23, 93-104.	0.1	17
579	Model-Based Planning and Delivery of Mass Vaccination Campaigns against Infectious Disease: Application to the COVID-19 Pandemic in the UK. <i>Vaccines</i> , 2021, 9, 1460.	2.1	8
580	Recent Advancements on COVID-19: A Comprehensive Review. <i>International Journal of General Medicine</i> , 2021, Volume 14, 10351-10372.	0.8	7
581	Advances in the design and development of SARS-CoV-2 vaccines. <i>Military Medical Research</i> , 2021, 8, 67.	1.9	26
583	COVID-19 Vaccines Cost-Effectiveness Analysis: A Scenario for Iran. <i>Vaccines</i> , 2022, 10, 37.	2.1	15
584	Vacunaci3n contra SARS-CoV-2 / COVID-19: Actualidad y perspectivas de vacunaci3n en Colombia. <i>Pediatría</i> , 2021, 54, 105-110.	0.2	0
585	Prevalence of Adverse Events Post-COVID-19 Vaccination amongst the Adult Zambian Population. <i>Journal of Biomedical Research & Environmental Sciences</i> , 2021, 2, 1315-1321.	0.1	1
586	Comparative Cohort Epidemiological Study of Collective Immunity against New Coronavirus Infection among Different Groups of Military Personnel. <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , 2021, 76, 661-668.	0.2	14
587	COVID-19: The question of genetic diversity and therapeutic intervention approaches. <i>Genetics and Molecular Biology</i> , 2021, 44, e20200452.	0.6	1
588	“Just do what you can” personal experience of medical university students working with COVID-19 patients. <i>Sociology of Medicine</i> , 2021, 20, 49-56.	0.2	0
589	Presence and quantity of antibodies after vaccination “Gam-COVID-Vac”. <i>Klinicheskaya Laboratornaya Diagnostika</i> , 2022, 67, 147-150.	0.2	2
590	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Specific T Cells and Antibodies in Coronavirus Disease 2019 (COVID-19) Protection: A Prospective Study. <i>Clinical Infectious Diseases</i> , 2022, 75, e1-e9.	2.9	25

#	ARTICLE	IF	CITATIONS
591	Safety and immunogenicity of SpikoGen [®] , an Advax-CpG55.2-adjuvanted SARS-CoV-2 spike protein vaccine: a phase 2 randomized placebo-controlled trial in both seropositive and seronegative populations. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1263-1271.	2.8	37
593	Global Scientific Research on SARS-CoV-2 Vaccines: A Bibliometric Analysis. <i>Cell Journal</i> , 2021, 23, 523-531.	0.2	4
594	Relationship between blood clots and COVID-19 vaccines: A literature review. <i>Open Life Sciences</i> , 2022, 17, 401-415.	0.6	6
595	Longitudinal Randomized Cohort Study of SARS-CoV-2 Antibody Seroprevalence in the St. Petersburg Population. <i>Viruses</i> , 2022, 14, 913.	1.5	5
596	The impact of vaccination against the new coronavirus infection on the morbidity of university students. <i>Russian Family Doctor</i> , 2022, 26, 21-26.	0.1	0
597	Epidemiological Features of COVID-19 in Northwest Russia in 2021. <i>Viruses</i> , 2022, 14, 931.	1.5	7
598	Development of a smartphone-based quantum dot lateral flow immunoassay strip for ultrasensitive detection of anti-SARS-CoV-2 IgG and neutralizing antibodies. <i>International Journal of Infectious Diseases</i> , 2022, 121, 58-65.	1.5	19
599	Evaluation of effectiveness of humoral immune response after vaccination with "CoviVac" [™] . <i>Medical Alphabet</i> , 2022, 1, 18-24.	0.0	2
600	Recent developments in SARS-CoV-2 vaccines: A systematic review of the current studies. <i>Reviews in Medical Virology</i> , 2023, 33, e2359.	3.9	17
601	COVID-19 Vaccines and the Efficacy of Currently Available Vaccines Against COVID-19 Variants. <i>Cureus</i> , 2022, , .	0.2	3
602	Efficacy versus abundance: Comparing vaccination schemes. <i>PLoS ONE</i> , 2022, 17, e0267840.	1.1	3
603	Vaccine Side Effects Following COVID-19 Vaccination Among the Residents of the UAE [™] An Observational Study. <i>Frontiers in Public Health</i> , 2022, 10, .	1.3	50
604	COVID-19 vaccine development: milestones, lessons and prospects. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 146.	7.1	153
605	Vaccines for Covid-19: An insight on their effectiveness and adverse effects. <i>Journal of Medical Virology</i> , 2022, , .	2.5	7
606	COVID-19 Vaccine Hesitancy Among Older Adolescents and Young Adults: A National Cross-Sectional Study in China. <i>Frontiers in Public Health</i> , 2022, 10, .	1.3	7
607	Development of a perfusion process for serum-free adenovirus vector herpes zoster vaccine production. <i>AMB Express</i> , 2022, 12, 58.	1.4	3
608	Anti-cancer Virotherapy in Russia: Lessons from the Past, Current Challenges and Prospects for the Future. <i>Current Pharmaceutical Biotechnology</i> , 2023, 24, 266-278.	0.9	3
609	Immunoinformatic paradigm predicts macrophage and T-cells epitope responses against globally conserved spike fragments of SARS CoV-2 for universal vaccination. <i>International Immunopharmacology</i> , 2022, , 108847.	1.7	0

#	ARTICLE	IF	CITATIONS
610	Safety and immunogenicity of Nanocovax, a SARS-CoV-2 recombinant spike protein vaccine: Interim results of a double-blind, randomised controlled phase 1 and 2 trial. <i>The Lancet Regional Health - Western Pacific</i> , 2022, 24, 100474.	1.3	13
611	Neutralization assays for SARS-CoV-2: Implications for assessment of protective efficacy of COVID-19 vaccines. <i>Indian Journal of Medical Research</i> , 2022, 155, 105.	0.4	2
612	Comparison of severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine side effects by age groups. <i>Revista Da Associação Médica Brasileira</i> , 2022, 68, 476-481.	0.3	3
613	The chimera of S1 and N proteins of SARS-CoV-2: can it be a potential vaccine candidate for COVID-19?. <i>Expert Review of Vaccines</i> , 2022, 21, 1071-1086.	2.0	3
614	Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial. <i>PLoS Medicine</i> , 2022, 19, e1003953.	3.9	27
615	Viral vector vaccines. <i>Current Opinion in Immunology</i> , 2022, 77, 102210.	2.4	28
616	COVID-19: VARIANTS, VACCINES, AND ADVERSE REACTIONS. <i>Innovare Journal of Medical Sciences</i> , 0, , 6-13.	0.2	0
617	Comprehensive narrative review of real-world COVID-19 vaccines: viewpoints and opportunities. <i>Medical Review</i> , 2022, 2, 169-196.	0.3	5
618	Preclinical study of formulated recombinant nucleocapsid protein, the receptor binding domain of the spike protein, and truncated spike (S1) protein as vaccine candidates against COVID-19 in animal models. <i>Molecular Immunology</i> , 2022, 149, 107-118.	1.0	2
620	COVID-19 exit strategy during vaccine implementation: a balance between social distancing and herd immunity. <i>Archives of Virology</i> , 0, , .	0.9	1
621	Comparison of IgA, IgG, and Neutralizing Antibody Responses Following Immunization With Moderna, BioNTech, AstraZeneca, Sputnik-V, Johnson and Johnson, and Sinopharm's COVID-19 Vaccines. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	33
623	Concerns and Challenges Related to Sputnik V Vaccination Against the Novel COVID-19 Infection in the Russian Federation: The Role of Mental Health, and Personal and Social Issues as Targets for Future Psychosocial Interventions. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	2
624	Sputnik V Effectiveness against Hospitalization with COVID-19 during Omicron Dominance. <i>Vaccines</i> , 2022, 10, 938.	2.1	15
625	The State-of-the-Art of Gene Editing and its Application to Viral Infections and Diseases Including COVID-19. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	5
626	Is the COVID-19 Pandemic Over? The Current Status of Boosters, Immunosenescence, Long Haul COVID, and Systemic Complications. <i>International Journal of Translational Medicine</i> , 2022, 2, 230-241.	0.1	0
627	Optimal vaccine roll-out strategies including social distancing for pandemics. <i>IScience</i> , 2022, 25, 104575.	1.9	5
628	Antibody and Memory B-Cell Immunity in a Heterogeneously SARS-CoV-2-Infected and -Vaccinated Population. <i>MBio</i> , 2022, 13, .	1.8	9
629	COVID-19 Vaccines: Update of the vaccines in use and under development. <i>Vacunas</i> , 2022, , .	1.1	6

#	ARTICLE	IF	CITATIONS
630	Long-term antibody response following SPUTNIK V primary vaccination in healthcare workers with and without history of SARS-CoV-2 infection: Prospective cohort study from a hospital in Argentina. <i>Vaccine: X</i> , 2022, 11, 100187.	0.9	4
631	Decavanadate interactions with the elements of the SARS-CoV-2 spike protein highlight the potential role of electrostatics in disrupting the infectivity cycle. <i>Journal of Inorganic Biochemistry</i> , 2022, 234, 111899.	1.5	7
632	COVID-19 vaccines portray the bright side of human creativity, but it means nothing until they prove their worth: A Study on Seroconversion after the first Dose of Covishield vaccine in central Kerala. <i>Indian Journal of Community Medicine</i> , 2022, 47, 213.	0.2	0
633	Seroprevalence of neutralizing antibodies against adenovirus type 26 and 35 in healthy populations from Guangdong and Shandong provinces, China. <i>Virologica Sinica</i> , 2022, 37, 716-723.	1.2	5
634	Coronavirus Disease 2019 Vaccination for Cancer Patients: Risk or Benefit?. <i>Revista Brasileira De Ginecologia E Obstetricia</i> , 2022, 44, 602-608.	0.3	1
635	Combining intramuscular and intranasal homologous prime-boost with a chimpanzee adenovirus-based COVID-19 vaccine elicits potent humoral and cellular immune responses in mice. <i>Emerging Microbes and Infections</i> , 2022, 11, 1890-1899.	3.0	12
636	Viral Vector Vaccine Development and Application during the COVID-19 Pandemic. <i>Microorganisms</i> , 2022, 10, 1450.	1.6	28
637	Global Trends in Nursing-Related Research on COVID-19: A Bibliometric Analysis. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	11
638	Investigating trends in those who experience menstrual bleeding changes after SARS-CoV-2 vaccination. <i>Science Advances</i> , 2022, 8, .	4.7	68
639	A Review on Immunological Responses to SARS-CoV-2 and Various COVID-19 Vaccine Regimens. <i>Pharmaceutical Research</i> , 2022, 39, 2119-2134.	1.7	10
640	The impact of COVID-19 vaccination programme in the Republic of San Marino: Focus on effectiveness of Gam-Covid-Vac. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1636-1643.	2.8	3
641	Assessment of post-vaccination collective immunity against new coronavirus infection (COVID-19) among servicemen of the Armed Forces of the Russian Federation. <i>Vestnik of Russian Military Medical Academy</i> , 2022, 24, 267-276.	0.1	3
642	SARS-CoV-2 herd immunity of the Kyrgyz population in 2021. <i>Medical Microbiology and Immunology</i> , 2022, 211, 195-210.	2.6	8
643	Insights into COVID-19 vaccines development: Translation from benchside to bedside. <i>Health Sciences Review</i> , 2022, 4, 100040.	0.6	1
644	Vacunas contra la COVID-19. <i>Ambiociencias</i> , 0, , 75-108.	0.0	1
645	Mix-and-Match COVID-19 Vaccinations (Heterologous Boost): A Review. <i>Infectious Disease Reports</i> , 2022, 14, 537-546.	1.5	23
646	A bibliometric analysis of COVID-19 publications in neurology by using the visual mapping method. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	14
647	Report of Adverse Effects Following Population-Wide COVID-19 Vaccination: A Comparative Study between Six Different Vaccines in Baja-California, Mexico. <i>Vaccines</i> , 2022, 10, 1196.	2.1	3

#	ARTICLE	IF	CITATIONS
648	Perspectives on Genetic Medicine for Cystic Fibrosis. <i>Current Gene Therapy</i> , 2022, 22, .	0.9	0
649	The Analysis of Anti-Epidemic Measures Carried Out in the Russian Federation in the Context of the COVID-19 Pandemic. <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , 2022, 77, 172-180.	0.2	0
650	A personal COVID-19 dendritic cell vaccine made at point-of-care: Feasibility, safety, and antigen-specific cellular immune responses. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	4
651	Drug hypersensitivity, in vitro tools, biomarkers, and burden with COVID-19 vaccines. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 3527-3537.	2.7	2
652	SARS-CoV-2 prefusion spike protein stabilized by six rather than two prolines is more potent for inducing antibodies that neutralize viral variants of concern. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	28
653	Sputnik-V reactogenicity and immunogenicity in the blood and mucosa: a prospective cohort study. <i>Scientific Reports</i> , 2022, 12, .	1.6	12
654	Clinical and immunological characteristics of vaccinated patients with COVID-19. <i>Chinese Medical Journal</i> , 0, Publish Ahead of Print, .	0.9	0
655	Integrase deficient lentiviral vector: prospects for safe clinical applications. <i>PeerJ</i> , 0, 10, e13704.	0.9	6
656	Evaluation of response to different COVID-19 vaccines in vaccinated healthcare workers in a single center in Iran. <i>Journal of Medical Virology</i> , 2022, 94, 5669-5677.	2.5	6
657	Heterologous immunization with adenovirus vectored and inactivated vaccines effectively protects against SARS-CoV-2 variants in mice and macaques. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
658	Latest in COVID-19 Vaccine 'Candidates' Race. <i>Infectious Disorders - Drug Targets</i> , 2022, 22, .	0.4	0
659	Immunogenicity and protectivity of intranasally delivered vector-based heterologous prime-boost COVID-19 vaccine Sputnik V in mice and non-human primates. <i>Emerging Microbes and Infections</i> , 2022, 11, 2229-2247.	3.0	8
660	The Sputnik V moment: biotech, biowarfare and COVID-19 vaccine development in Russia and in former Soviet satellite states. <i>East European Politics</i> , 2022, 38, 571-593.	0.9	3
661	Accelerating model-informed decisions for COVID-19 vaccine candidates using a model-based meta-analysis approach. <i>EBioMedicine</i> , 2022, 84, 104264.	2.7	4
662	COVID-19: Vaccines and therapeutics. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2022, 75, 128987.	1.0	4
663	Hazards of vaccinating the way out of Covid-19 pandemic: Study of adverse events following immunization (Aefi) in India. <i>Medical Journal of Dr D Y Patil Vidyapeeth</i> , 2022, .	0.0	0
664	Development of Severe Acute Respiratory Syndrome Corona Virus-2 (SARS-COV-2) Vaccines. <i>Nigerian Journal of Medicine: Journal of the National Association of Resident Doctors of Nigeria</i> , 2022, 31, 484.	0.0	0
665	SARS-CoV-2 Vaccine Against Virus: Mission Accomplished!?. , 2022, , 561-574.		0

#	ARTICLE	IF	CITATIONS
666	Acute Ischemic Stroke in the Context of SARS-CoV-2 Vaccination: A Systematic Review. <i>Neuropsychiatric Disease and Treatment</i> , 0, Volume 18, 1907-1916.	1.0	3
667	Is Russia's Research Ethics Culture Reliable?. <i>Ethics & Human Research</i> , 0, , .	0.5	0
668	Identification of the effects of COVID-19 on patients with pulmonary fibrosis and lung cancer: a bioinformatics analysis and literature review. <i>Scientific Reports</i> , 2022, 12, .	1.6	6
669	Developing dendritic cell for SARS-CoV-2 vaccine: Breakthrough in the pandemic. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
670	Vaccine effectiveness against referral to hospital after SARS-CoV-2 infection in St. Petersburg, Russia, during the Delta variant surge: a test-negative case-control study. <i>BMC Medicine</i> , 2022, 20, .	2.3	8
671	COVID-19 vaccines effectiveness against symptomatic SARS-CoV-2 during Delta variant surge: a preliminary assessment from a case-control study in St. Petersburg, Russia. <i>BMC Public Health</i> , 2022, 22, .	1.2	4
672	COVID-19 Vaccinating Russian Medical Students's Challenges and Solutions: A Cross-Sectional Study. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 11556.	1.2	2
673	COVID-19 Infection Risk Following Elective Arthroplasty and Surgical Complications in COVID-19-vaccinated Patients: A Multicenter Comparative Cohort Study. <i>Arthroplasty Today</i> , 2022, 18, 76-83.	0.8	4
674	Gene Therapy Cargoes Based on Viral Vector Delivery. <i>Current Gene Therapy</i> , 2023, 23, 111-134.	0.9	5
675	A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies. <i>Journal of Biomedical Science</i> , 2022, 29, .	2.6	64
676	Development of variant-proof severe acute respiratory syndrome coronavirus 2, pan-sarbecovirus, and pan-coronavirus vaccines. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	12
677	A novel vaccine based on SARS-CoV-2 CD4+ and CD8+ T cell conserved epitopes from variants Alpha to Omicron. <i>Scientific Reports</i> , 2022, 12, .	1.6	8
678	A Hitchhiker's Guide to Worldwide COVID-19 Vaccinations: A Detailed Review of Monovalent and Bivalent Vaccine Schedules, COVID-19 Vaccine Side Effects, and Effectiveness Against Omicron and Delta Variants. <i>Cureus</i> , 2022, , .	0.2	10
679	The use of adenoviral vectors in gene therapy and vaccine approaches. <i>Genetics and Molecular Biology</i> , 2022, 45, .	0.6	3
680	Stabilized recombinant SARS-CoV-2 spike antigen enhances vaccine immunogenicity and protective capacity. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	12
681	A comprehensive review on variants of SARS-CoVs-2: Challenges, solutions and open issues. <i>Computer Communications</i> , 2023, 197, 34-51.	3.1	13
683	A Comprehensive Review on the Current Vaccines and Their Efficacies to Combat SARS-CoV-2 Variants. <i>Vaccines</i> , 2022, 10, 1655.	2.1	12
684	Variants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Vaccine Effectiveness. <i>Vaccines</i> , 2022, 10, 1751.	2.1	10

#	ARTICLE	IF	CITATIONS
685	Sputnik Light and Sputnik V Vaccination Is Effective at Protecting Medical Personnel from COVID-19 during the Period of Delta Variant Dominance. <i>Vaccines</i> , 2022, 10, 1804.	2.1	9
686	Association of COVID-19 Vaccinations With Intensive Care Unit Admissions and Outcome of Critically Ill Patients With COVID-19 Pneumonia in Lombardy, Italy. <i>JAMA Network Open</i> , 2022, 5, e2238871.	2.8	19
687	Analysis and comparison of anti-RBD neutralizing antibodies from AZD-1222, Sputnik V, Sinopharm and Covaxin vaccines and its relationship with gender among health care workers. <i>Immunity and Ageing</i> , 2022, 19, .	1.8	5
688	Peptide ILE-GLU-TRP (Stemokin) Potential Adjuvant Stimulating a Balanced Immune Response. <i>International Journal of Peptide Research and Therapeutics</i> , 2022, 28, .	0.9	1
689	Importance of the COVID-19 Vaccine Booster Dose in Protection and Immunity. <i>Vaccines</i> , 2022, 10, 1708.	2.1	3
690	An ELISA Platform for the Quantitative Analysis of SARS-CoV-2 RBD-neutralizing Antibodies As an Alternative to Monitoring of the Virus-Neutralizing Activity. , 2022, 14, 109-119.		2
691	An Analysis of the COVID-19 Situation in India in Terms of Testing, Treatment, Vaccine Acceptance and National Economic Performance. <i>International Journal of Public Health</i> , 0, 67, .	1.0	1
692	Role of next-generation sequencing in diagnosing, tracking and vaccine development of severe acute respiratory syndrome coronavirus 2. <i>Journal of the Academy of Clinical Microbiologists</i> , 2022, 24, 25.	0.2	0
693	SARS-CoV-2 spike conformation determines plasma neutralizing activity elicited by a wide panel of human vaccines. <i>Science Immunology</i> , 2022, 7, .	5.6	42
694	Vaccines for the Prevention of Coronavirus Disease 2019 in Older Adults. <i>Infectious Disease Clinics of North America</i> , 2023, 37, 27-45.	1.9	6
695	Safety and immunogenicity of an AS03-adjuvanted plant-based SARS-CoV-2 vaccine in Adults with and without Comorbidities. <i>Npj Vaccines</i> , 2022, 7, .	2.9	10
696	An attenuated vaccinia vaccine encoding the severe acute respiratory syndrome coronavirus-2 spike protein elicits broad and durable immune responses, and protects cynomolgus macaques and human angiotensin-converting enzyme 2 transgenic mice from severe acute respiratory syndrome coronavirus-2 and its variants. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	4
697	Lessons learned from COVID-19 pandemic: Vaccine platform is a key player. <i>Process Biochemistry</i> , 2023, 124, 269-279.	1.8	2
698	COVID-19 signalome: Potential therapeutic interventions. <i>Cellular Signalling</i> , 2023, 103, 110559.	1.7	5
699	COVID-19 vaccines: Update of the vaccines in use and under development. <i>Vacunas (English Edition)</i> , 2022, 23, S88-S102.	0.3	0
700	Presentations at the UK National Immunisation Conference. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	1
701	Respiratory viral infections and their role in human cardiovascular diseases. <i>Sibirskij Å¾urnal KliniÅskoj I ÅksperimentalĒnoj Mediciny</i> , 0, , .	0.1	0
702	Assessing the long-stand antibody response induced by COVID-19 vaccines: A study in an educational cohort in San Luis, Argentina. <i>Vaccine</i> , 2022, , .	1.7	0

#	ARTICLE	IF	CITATIONS
703	130th anniversary of virology. <i>Voprosy Virusologii</i> , 2022, 67, 357-384.	0.1	2
704	Incubation Temperature and Period During Denarase Treatment and Microfiltration Affect the Yield of Recombinant Adenoviral Vectors During Downstream Processing. <i>Molecular Biotechnology</i> , 0, , .	1.3	0
705	Nasal vaccines: solutions for respiratory infectious diseases. <i>Trends in Molecular Medicine</i> , 2023, 29, 124-140.	3.5	10
706	Neurological Complications Following COVID-19 Vaccination. <i>Current Neurology and Neuroscience Reports</i> , 2023, 23, 1-14.	2.0	12
707	Nanomaterials to combat SARS-CoV-2: Strategies to prevent, diagnose and treat COVID-19. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	3
709	Different Formulations of Inactivated SARS-CoV-2 Vaccine Candidates in Human Compatible Adjuvants: Potency Studies in Mice Showed Different Platforms of Immune Responses. <i>Viral Immunology</i> , 2022, 35, 663-672.	0.6	2
710	Knowledge And Attitudes Toward the COVID-19 Vaccine Among India's General Rural Population. <i>Vacunas</i> , 2022, , .	1.1	0
711	Nanotechnology in COVID-19 Vaccines. , 2023, , 14-26.		0
712	Ethical Evaluations of Clinical Trials in France: Towards European Standardization. <i>Philosophy and Medicine</i> , 2023, , 405-421.	0.3	0
713	Biphenyl furanocoumarin compounds inhibit SARS-CoV-2 spike pseudovirus infection by binding ACE2. <i>New Journal of Chemistry</i> , 2023, 47, 2651-2658.	1.4	1
714	Updated Insights into the T Cell-Mediated Immune Response against SARS-CoV-2: A Step towards Efficient and Reliable Vaccines. <i>Vaccines</i> , 2023, 11, 101.	2.1	14
715	Full protection from SARS-CoV-2 brain infection and damage in susceptible transgenic mice conferred by MVA-CoV2-S vaccine candidate. <i>Nature Neuroscience</i> , 2023, 26, 226-238.	7.1	14
716	COVID-19 Vaccinesâ€™ All You Want to Know. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2023, 44, 143-172.	0.8	4
717	Sperm DNA fragmentation in men vaccinated with Gam-COVID-Vac (Sputnik V). <i>Andrologia I Genital'naa Hirurgia</i> , 2023, 23, 64-73.	0.1	0
718	An experience of scaling and intensifying the industrial production of the Gam-COVID-Vac vector adenovirus vaccine in the limiting conditions of the pandemic. <i>BIOpreparations Prevention Diagnosis Treatment</i> , 2022, 22, 382-391.	0.2	0
719	Selection of a SARS-CoV-2 antibody quantification method and development of an antibody reference standard for ELISA to test immunoglobulin preparations. <i>BIOpreparations Prevention Diagnosis Treatment</i> , 2022, 22, 392-404.	0.2	0
720	Aspects and issues of marketing authorisation and use of medicinal products for COVID-19 prevention during the pandemic. <i>BIOpreparations Prevention Diagnosis Treatment</i> , 2022, 22, 361-381.	0.2	2
721	Immunogenicity evaluation of Gam-COVID-Vac (Sputnik V). <i>BIOpreparations Prevention Diagnosis Treatment</i> , 2022, 22, 435-445.	0.2	3

#	ARTICLE	IF	CITATIONS
722	Cohort Profile:The Danish National Cohort Study of Effectiveness and Safety of SARS-CoV-2 vaccines (ENFORCE). <i>BMJ Open</i> , 2022, 12, e069065.	0.8	5
723	Revaccination in Age-Risk Groups with Sputnik V Is Immunologically Effective and Depends on the Initial Neutralizing SARS-CoV-2 IgG Antibodies Level. <i>Vaccines</i> , 2023, 11, 90.	2.1	3
724	Coronavirus-Specific Antibody and T Cell Responses Developed after Sputnik V Vaccination in Patients with Chronic Lymphocytic Leukemia. <i>International Journal of Molecular Sciences</i> , 2023, 24, 416.	1.8	1
725	History of vaccine: from centuries to present. , 2022, , 3-16.		0
726	Cancer vaccineâ€™s multiverse and the future ahead. , 2022, , 335-360.		0
727	Adverse events and SARS-CoV-2 antibody responses after immunization with Sputnik V, ChAdOx1-S, and BBIBP-CorV vaccines in people with HIV. <i>Aids</i> , 2023, 37, 941-946.	1.0	1
728	Immunogenicity Characterization of COVID-19 Vaccines: A Systematic Review and Meta-analysis. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 0, 56, .	0.4	2
729	The Potential of Nanobodies for COVID-19 Diagnostics and Therapeutics. <i>Molecular Diagnosis and Therapy</i> , 2023, 27, 193-226.	1.6	6
730	Evaluation of Short-Term Side Effects Following the First Dose of COVID-19 Vaccines Among Physicians and Dentists: A Cross-Sectional Study from India. <i>Journal of Multidisciplinary Healthcare</i> , 0, Volume 16, 161-174.	1.1	6
731	Applications of genetic engineering in COVID-19. , 2023, , 219-237.		0
732	COVID-19 Vaccination and Alcohol Consumption: Justification of Risks. <i>Pathogens</i> , 2023, 12, 163.	1.2	4
733	Combating the challenges of COVID-19 pandemic: Insights into molecular mechanisms, immune responses and therapeutics against SARS-CoV-2. <i>Oxford Open Immunology</i> , 2023, 4, .	1.2	3
734	Can COVID-19 Vaccines Induce Premature Non-Communicable Diseases: Where Are We Heading to?. <i>Vaccines</i> , 2023, 11, 208.	2.1	5
735	T-Cell Immunity in COVID-19-Recovered Individuals and Individuals Vaccinated with the Combined Vector Vaccine Gam-COVID-Vac. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1930.	1.8	0
736	Thermostability of Vaccines. , 2023, , 33-79.		0
737	Reoccurrence of Covid-19 infection in vaccinated Iraqi community. <i>AIP Conference Proceedings</i> , 2023, , .	0.3	0
738	Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	23
739	Comparative assessment of efficacy and immunogenicity of Gam-COVID-Vac and CoviVac vaccines against SARS-CoV-2. <i>Profilakticheskaya Meditsina</i> , 2022, 25, 82.	0.2	1

#	ARTICLE	IF	CITATIONS
740	Respiratory viral infections and their role in human cardiovascular diseases. <i>Sibirskij Āurnal KliniĀeskoj I ĀksperimentalĀnoj Mediciny</i> , 2023, 37, 14-21.	0.1	0
741	An Overview of Current Accomplishments and Gaps of COVID-19 Vaccine Platforms and Considerations for Next Generation Vaccines. <i>Journal of Pharmaceutical Sciences</i> , 2023, 112, 1345-1350.	1.6	3
742	COVID-19 therapy and vaccination: a clinical narrative review. <i>Drugs in Context</i> , 0, 12, 1-11.	1.0	10
743	Assesment of specific T-cell immunity to SARS-CoV-2 virus antigens in COVID-19 reconvalescents. <i>Voprosy Virusologii</i> , 2023, 67, 527-537.	0.1	1
744	Adenoviral Vector-Based Vaccine Platform for COVID-19: Current Status. <i>Vaccines</i> , 2023, 11, 432.	2.1	17
745	Adverse events following immunisation with the first dose of sputnik V among Iranian health care providers. <i>Clinical and Experimental Vaccine Research</i> , 2023, 12, 25.	1.1	0
746	SARS-CoV-2 S Glycoprotein Stabilization Strategies. <i>Viruses</i> , 2023, 15, 558.	1.5	1
747	The Coming of Age of Nucleic Acid Vaccines during COVID-19. <i>MSystems</i> , 2023, 8, .	1.7	5
748	Preventive Efficacy of Domestic Vaccines against a New Coronavirus Infection in the Immunization of Employees of Medical Organizations. <i>Epidemiologiya I Vaktsinoprofilaktika</i> , 2023, 22, 22-27.	0.2	3
749	Investigating antigenic features of the SARS-CoV-2 isolated in Russian Federation in 2021Ā2022 by hyperimmune mouse serum neutralisation. <i>Russian Journal of Infection and Immunity</i> , 2023, 13, 37-45.	0.2	1
750	Dissection of Antibody Responses of Gam-COVID-Vac-Vaccinated Subjects Suggests Involvement of Epitopes Outside RBD in SARS-CoV-2 Neutralization. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5104.	1.8	2
751	Immunogenicity and safety of a recombinant adenovirus type-5 COVID-19 vaccine in adults: Data from a randomised, double-blind, placebo-controlled, single-dose, phase 3 trial in Russia. <i>PLoS ONE</i> , 2023, 18, e0278878.	1.1	1
753	Human memory T cell dynamics after aluminum-adjuvanted inactivated whole-virion SARS-CoV-2 vaccination. <i>Scientific Reports</i> , 2023, 13, .	1.6	0
755	rAAV expressing recombinant antibody for emergency prevention and long-term prophylaxis of COVID-19. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
756	Dendrimer-Mediated Delivery of DNA and RNA Vaccines. <i>Pharmaceutics</i> , 2023, 15, 1106.	2.0	7
757	Vaccine Basics and the Development and Rollout of COVID-19 Vaccines. , 2024, , 326-348.		0
758	An assessment of the strategy and status of COVID-19 vaccination in India. <i>Immunologic Research</i> , 2023, 71, 565-577.	1.3	3
759	Longitudinal Follow-Up of the Immunity to SARS-CoV-2 in Health Care Workers in Argentina: Persistence of Humoral Response and Neutralizing Capacity after Sputnik V Vaccination. <i>MSphere</i> , 0, , .	1.3	0

#	ARTICLE	IF	CITATIONS
760	Side Effects Comparison of Coronavirus Vaccines Among Healthcare Workers in Shoushtar, Iran. BMC Clinical Pathology, 2023, 16, 2632010X2311667.	0.7	1
761	Comparative analysis of humoral immune response upon the three first vaccines applied in Argentina: IgG production and neutralizing capacity against SARS-CoV-2. Heliyon, 2023, 9, e15211.	1.4	1
762	Research Advances in SARS-Cov-2 Vaccination of Bellâ€™s Palsy. Advances in Clinical Medicine, 2023, 13, 5965-5971.	0.0	0
767	A profound perception into manifestation of lifesaver. AIP Conference Proceedings, 2023, , .	0.3	0
768	The effect of COVID-19 on cancer immunotherapy and cancer care. , 2024, , 289-310.e7.		0
773	The role of vaccines in the COVID-19 pandemic: what have we learned?. Seminars in Immunopathology, 0, , .	2.8	13
776	Genetic-Based Vaccine Vectors. , 2023, , 1374-1396.e11.		0
777	Technologies for Making New Vaccines. , 2023, , 1350-1373.e9.		0
778	Coronavirus Vaccines. , 2023, , 248-257.e4.		0
784	Nanotechnology of inhalable vaccines for enhancing mucosal immunity. Drug Delivery and Translational Research, 0, , .	3.0	0
786	Protection of COVID-19 vaccine in general and special population. , 2023, , .		0
810	Therapeutic landscape of SARS-CoV-2. , 2024, , 83-99.		0
814	Enhancing Immunological Memory: Unveiling Booster Doses to Bolster Vaccine Efficacy Against Evolving SARS-CoV-2 Mutant Variants. Current Microbiology, 2024, 81, .	1.0	0